https://trial.medpath.com/news/656a7e6c3d70a8b4/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/71c886dc945ead2f/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T13:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/6a71329bf2e495a6/pharmacogenomic-study-of-selected-genes-and-its-association-with-amlod-dove-medical-press 2024-10-28T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/9da3ab85e2ee1300/fda-grants-orphan-drug-designation-to-and017-for-the-treatment-of-sickle-cell-disease 2024-10-28T13:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/2e5ea990a5b667fa/dr-reddy-s-launches-medication-to-treat-chronic-constipation-the-week 2024-10-28T13:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/19fd34788a6333df/j-j-s-darzalex-regimen-approved-by-ec-for-newly-diagnosed-multiple-myeloma-pmlive 2024-10-28T13:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/ac2e3225a1b48541/ctdna-generates-momentum-in-adjuvant-stage-ii-iii-colon-cancer-setting-onclive 2024-10-28T13:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/42ea6cb4ad4c125d/haystack-project-working-with-lawmakers-on-rare-disease-approval-legislation 2024-10-28T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/847c2f546f13c42a/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T12:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/53c194f6ec7dfca5/inhaled-reliever-therapies-for-asthma-a-systematic-review-and-meta-analysis 2024-10-28T12:58:26+00:00 weekly 0.7 https://trial.medpath.com/news/2bfc83f7ff9359d3/fda-approves-iterum-s-orlynvah-nda-for-uuti-treatment-pharmaceutical-technology 2024-10-28T12:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/e78a929980c5dd16/fda-approves-iterum-s-orlynvah-for-urinary-tract-infection-world-pharmaceutical-frontiers 2024-10-28T12:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/9656133ad4dae58a/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-28T12:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/35c3962d9dcf0ddf/fda-approves-new-uti-drug-for-women-who-have-run-out-of-options-kff-health-news 2024-10-28T12:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/7b1712f34851deda/rejuvenate-biomed-partners-with-nihr-leicester-brc-for-phase-2-trial-of-novel-copd-related-sarcopenia-treatment 2024-10-28T12:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/641d11f5449851b6/fda-approves-dual-energy-system-for-af-ablation-tctmd-com 2024-10-28T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/3697d15d270aeaee/cancer-research-uk-kisoji-biotechnology-collaborate-to-advance-the-first-naked-antibody 2024-10-28T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/4f9ec557299ba8d9/recce-pharmaceuticals-receives-interim-efficacy-data-and-safety-approval-to-continue 2024-10-28T12:29:07+00:00 weekly 0.7 https://trial.medpath.com/news/ad729341c2d7a9ac/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/dad7294291bbbd4c/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/news/53306ff04ad378da/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/4465799e1cf1eb47/msd-moderna-start-phase-3-adjuvant-lung-cancer-trial-pharmaphorum 2024-10-28T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/ffac60d4f3b2a92f/radium-223-and-enzalutamide-game-changing-peace-iii-phase-3-data-in-mcrpc 2024-10-28T12:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/fe767a72779ef99e/inmune-bio-inc-to-host-webinar-on-cognitive-testing-using-emacc-and-cdr-sb 2024-10-28T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/3778a77c9b4f1f40/iterum-wins-fda-approval-for-oral-uti-antibiotic-seeks-strategic-transaction-for-asset 2024-10-28T12:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/b1531ca910771a1c/biosenic-provides-third-quarter-2024-business-update-globenewswire 2024-10-28T12:02:38+00:00 weekly 0.7 https://trial.medpath.com/news/8bf3ccfca8cbdf53/validation-and-refinement-of-the-2022-european-leukaemianet-genetic-risk-classification-nature 2024-10-28T11:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/22868540b4578efe/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-stock-titan 2024-10-28T11:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/b288f39c69db43fe/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access 2024-10-28T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/news/2d356a11a925da6f/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-biospace 2024-10-28T11:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/ee84d6fd3e55a053/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-28T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/120b4a18aa8acc66/t-neuro-pharma-to-presents-expanded-alzheimer-s-disease-blood-biomarker-assay-at 2024-10-28T11:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/b01d922c3e2120b9/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-morningstar 2024-10-28T11:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/a4b6759c61841cd3/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T11:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/9126a61697c2df3c/fda-clears-tyra-biosciences-trial-for-dwarfism-drug-investing-com 2024-10-28T11:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/618b7841713ae7f6/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access-stock-titan 2024-10-28T11:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/a809478bf124234a/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-stock-titan 2024-10-28T11:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/45625ba1c9561088/eyepoint-pharmaceuticals-announces-positive-interim-16-week-globenewswire 2024-10-28T11:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/8211c1f4845dfc46/a-digital-decentralized-trial-of-exercise-therapy-in-patients-with-cancer-nature 2024-10-28T11:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/d1d0fca37adc924e/bristol-myers-squibb-to-present-new-clinical-and-health-economics-and-outcomes 2024-10-28T11:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/1826687c3b8580dd/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-yahoo-finance 2024-10-28T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/78cd70f49810f5bb/ocugen-clinical-showcase-highlighting-progress-in-retinal-gene-therapy-clinical-trials-in 2024-10-28T10:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/40ee887fa88e0897/levicept-to-present-phase-ii-data-at-acr-convergence-2024-biospace 2024-10-28T10:44:36+00:00 weekly 0.7 https://trial.medpath.com/news/6ea609a0efd4141b/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T10:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/d0eeea57b0f40ead/eli-lilly-gets-nod-to-launch-blockbuster-weight-loss-drug-in-hong-kong-medwatch 2024-10-28T10:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/e4325319f927b685/sebetralstat-shows-promise-in-phase-3-hae-trial-investing-com 2024-10-28T10:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/e1216cf383b52ad4/astellas-pulls-geographic-atrophy-drug-filing-in-the-eu-pharmaphorum 2024-10-28T10:36:15+00:00 weekly 0.7 https://trial.medpath.com/news/3b6dba74754f89c7/ozempic-wegovy-or-mounjaro-the-battle-of-the-weight-loss-injections-evening-standard 2024-10-28T10:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/9582a88e9909a164/ocugen-clinical-showcase-highlighting-progress-in-retinal-globenewswire 2024-10-28T10:33:56+00:00 weekly 0.7 https://trial.medpath.com/news/ca909a35947fccb8/ideaya-biosciences-announces-ind-clearance-for-werner-helicase-development-pr-newswire 2024-10-28T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/211b16f72d9bbc6b/brainstorm-cell-therapeutics-presented-positive-survival-data-from-nurown-r-expanded 2024-10-28T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/703a403149402f2c/novartis-fabhalta-shows-positive-outcomes-in-c3-glomerulopathy-treatment 2024-10-28T10:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/17baa0fbf58f29f4/skin-patch-uses-imperceptible-electric-zaps-to-heal-wounds-without-drugs 2024-10-28T10:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/a4040bd0e0f88d72/new-hope-against-a-rare-aggressive-form-of-thyroid-cancer 2024-10-28T10:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ce3e9b9a58a739dd/ozempic-curbs-kidney-disease-in-obese-people-without-diabetes 2024-10-28T10:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/403d02ec19b90b0f/legislation-will-allow-wvu-researcher-to-study-buprenorphine-at-new-martinsville-clinic 2024-10-28T10:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/81267c9a12cf182b/astellas-withdraws-europe-acp-application-for-amd-treatment-pharmaceutical-technology 2024-10-28T09:52:12+00:00 weekly 0.7 https://trial.medpath.com/news/984d0f430a3a193c/levicept-to-present-phase-ii-data-at-acr-convergence-2024-morningstar 2024-10-28T09:48:51+00:00 weekly 0.7 https://trial.medpath.com/news/276aaf61c6850967/eli-lilly-s-weight-loss-drug-mounjaro-set-for-hong-kong-launch-report-investing-com-uk 2024-10-28T09:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/715805550a299f42/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines-pharmabiz 2024-10-28T09:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/39d50aff6aa5a82b/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T09:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/a8282cc05c321520/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T09:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/4de5412896f83237/ideaya-reports-positive-interim-phase-1-expansion-data-of-ide397-in-mtap-deletion-pharmabiz 2024-10-28T08:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/478f6af65d78a972/dtab-recommends-amendment-of-mdr-2017-to-include-eu-under-rule-63-pharmabiz 2024-10-28T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/b3effb6c84b1cc8f/yuhan-s-q3-operating-profit-surges-690-on-us-sale-of-lung-cancer-drug-lazertinib-kbr 2024-10-28T07:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/e048a1c657afb295/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T07:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/72a9428a2e2debc4/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis-astrazeneca 2024-10-28T07:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/84dd931223a81ad4/automatic-setting-optimization-for-robotic-upper-extremity-rehabilitation-in-patients-with-nature 2024-10-28T06:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/d3cc32c6dfa2519e/a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for 2024-10-28T06:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/ceaefdc27b6ef636/global-tb-crisis-persists-chest-2024-leaders-highlight-post-covid-challenges-and-rising-death-toll 2024-10-28T06:13:24+00:00 weekly 0.7 https://trial.medpath.com/news/42bdbb79318ff22e/vanderbilt-health-study-specialty-pharmacists-drive-significant-cost-savings-in-high-cost-medication-management 2024-10-28T05:52:21+00:00 weekly 0.7 https://trial.medpath.com/news/6a830d9ce21c2b1c/longeveron-r-presents-lomecel-btm-long-term-transplant-free-survival-data-in-biospace 2024-10-28T05:51:03+00:00 weekly 0.7 https://trial.medpath.com/news/d34274450c9d7d43/phase-3-trial-assesses-clazakizumab-in-kidney-transplant-recipients-with-caamr 2024-10-28T05:43:19+00:00 weekly 0.7 https://trial.medpath.com/news/d09a65b76da37b1b/lenz-therapeutics-reports-positive-phase-3-results-for-lnz100-in-presbyopia-trial-in-china 2024-10-28T05:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/9d4006bddb9fc660/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-28T05:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/1dfb130c6c605978/celltrion-s-phase-3-trial-confirms-yuflyma-s-interchangeability-with-humira-kbr 2024-10-28T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/cc6801630b9e6311/development-of-a-prognosis-prediction-model-for-pediatric-sepsis-based-jir 2024-10-28T04:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/71aed86d7e3f5a69/dimerix-announces-key-developments-in-kidney-disease-trials-markets-insider 2024-10-28T04:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/a4db2405acc74183/eu-advances-critical-medicines-act-to-reduce-asian-supply-chain-dependence 2024-10-28T04:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/5ceb0c39fb422ec7/sarepta-s-recent-elevidys-presentations-leave-duchenne-community-wanting-biospace 2024-10-28T04:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/5e53e4ffef61749c/evolving-fda-accelerated-approval-pathway-suffers-spate-of-withdrawals-biospace 2024-10-28T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/98fa23fe05912dbc/opinion-new-therapies-are-set-to-upend-treatment-of-genetic-disorder-aatd-biospace 2024-10-28T04:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/bd572877f170d64b/rising-gynecological-cancer-cases-prompt-push-for-enhanced-research-and-awareness 2024-10-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/de17247d104492c8/nihr-to-launch-new-ps15-million-funding-for-uk-australia-clinical-trials-pharmabiz 2024-10-28T03:29:15+00:00 weekly 0.7 https://trial.medpath.com/news/3fffc9e6e534a5a7/astragalus-polysaccharides-improve-adjuvant-chemotherapy-induced-fatigue-for-patients 2024-10-28T03:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/b3834e6e53f25e40/astellas-pharma-withdraws-eu-application-for-key-drug-markets-insider 2024-10-28T03:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/f9469daa8603c5f5/dimerix-limited-announces-update-on-parasol-scientific-workshop-marketscreener 2024-10-28T03:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/e96c594b6e9a091d/former-seagen-ceo-leads-ottimo-pharma-s-novel-cancer-immunotherapy-development 2024-10-28T02:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/faca7e22747097ca/social-media-emerges-as-powerful-tool-for-rare-disease-trial-recruitment-reports-40-response-rate 2024-10-28T02:45:25+00:00 weekly 0.7 https://trial.medpath.com/news/c9620ced684bc3fe/a-syk-inhibitor-for-the-treatment-of-autoimmune-disorders 2024-10-28T02:35:47+00:00 weekly 0.7 https://trial.medpath.com/news/4df45bff0fdcdf9f/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-tradingview 2024-10-28T02:33:12+00:00 weekly 0.7 https://trial.medpath.com/news/673334491a293eb3/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T02:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/669782cce2c86375/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-kfgo 2024-10-28T02:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/f274e17ea72b81cb/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T02:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/0d59bd4f5b9c9b6b/timothy-ritter-md-real-world-data-supporting-fecal-microbiota-for-recurrent-c-diff 2024-10-28T01:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/b3dc6f4c0d5f2475/fda-announces-device-trial-participation-snapshots-food-drugs-healthcare-life-sciences 2024-10-28T01:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/1e04233a52eae81b/perioperative-sintilimab-and-neoadjuvant-anlotinib-plus-chemotherapy-for-resectable-non-nature 2024-10-28T01:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/08869c4140acf073/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/14cb79f55a0e3026/day-4-recap-fall-clinical-2024-dermatology-times 2024-10-28T01:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/bd0fb9eed5aae70a/corxel-and-lenz-therapeutics-announce-positive-topline-data-globenewswire 2024-10-28T01:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/b62e50934db8e0fb/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/d2ae0045aee55272/zegocractin-significantly-improves-acute-pancreatitis-symptoms-in-phase-2-carpo 2024-10-28T01:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/6e663632c0a43428/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-markets-insider 2024-10-28T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/958d81a1932bdd5e/infliximab-improves-ulcerative-colitis-crohn-s-disease-regardless-of-immunosuppressants 2024-10-28T00:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/67817bef222f1764/clinical-trial-highlights-efficacy-of-imlifidase-for-kidney-transplant-recipients-news-medical 2024-10-27T23:54:44+00:00 weekly 0.7 https://trial.medpath.com/news/5410eba3cb495160/astellas-pharma-withdraws-eu-application-for-key-drug-tipranks-com 2024-10-27T23:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/a226a7d3a1618327/pharmacovigilance-of-drug-drug-interactions-with-nirmatrelvir-ritonavir-springer-medizin 2024-10-27T23:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/091827ade5deaec4/dupilumab-proves-effective-in-chronic-spontaneous-urticaria-medpage-today 2024-10-27T23:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/0bec82adb6a88b3b/novel-drug-leads-to-responses-in-waldenstrom-macroglobulinemia-oncology-nursing-news 2024-10-27T23:07:03+00:00 weekly 0.7 https://trial.medpath.com/news/7b0b22f899a65977/interim-align-data-atrasentan-cuts-proteinuria-in-iga-nephropathy-medpage-today 2024-10-27T22:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/c11989fe5c3122db/exact-sciences-presents-multiple-studies-at-acg-2024-demonstrating-leadership-in-quantisnow 2024-10-27T22:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/1aaef8d3e33470c5/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-quantisnow 2024-10-27T22:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/03ddbf3ef5518b34/can-merrimack-get-a-high-five 2024-10-27T21:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/364f0fa8163680a9/ozempic-shows-promise-against-alzheimer-s-disease-the-pinnacle-gazette 2024-10-27T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/d5b1cc82208d0986/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-tipranks-com 2024-10-27T20:21:22+00:00 weekly 0.7 https://trial.medpath.com/news/fea815772bdd37c5/study-reveals-comparable-efficacy-of-clascoterone-trifarotene-and-tazarotene-in-acne-treatment 2024-10-27T20:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/c5d42004d1e5579c/patient-reported-outcomes-for-roflumilast-foam-highlighted-for-seborrheic-dermatitis 2024-10-27T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/80e62d4f0c215828/origin-ole-data-solidify-atacicept-disease-modifying-potential-for-iga-nephropathy 2024-10-27T19:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/a80f0bca17c3eea8/new-data-highlight-long-term-benefits-of-heartflow-s-ai-based-cad-evaluations 2024-10-27T19:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/56aa2b9233a70602/longeveron-r-presents-lomecel-btm-long-term-transplant-free-globenewswire 2024-10-27T19:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/8b7f855ee754220d/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-stock-titan 2024-10-27T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/5eaa03ab90839ed8/emmy-graber-mb-mba-shares-top-clinical-pearls-on-lasers-erythema-treatments-and 2024-10-27T17:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/2413c266a3dcd8bf/unpack-the-latest-fda-approvals-and-updates-including-a-new-dosage-for-her2-cancers 2024-10-27T17:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/6bc9d812afad7db5/transcatheter-arterial-chemoembolization-plus-sorafenib-versus-transcatheter-arterial-nature 2024-10-27T16:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/6ccb7b85e56abb43/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-morningstar 2024-10-27T16:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/1617d412dfe74e05/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T16:45:40+00:00 weekly 0.7 https://trial.medpath.com/news/d1cd9793eb1ab22d/acg-presidential-plenary-to-highlight-analysis-of-xifaxan-r-rifaximin-risk-reduction-of 2024-10-27T16:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/5d503dc10245d9da/kidney-compass-semaglutide-for-nondiabetic-kidney-disease-with-hiddo-heerspink-phd 2024-10-27T16:20:05+00:00 weekly 0.7 https://trial.medpath.com/news/537534e56dbf6d89/painkiller-taken-by-millions-could-raise-risk-of-heart-attack-by-50-per-cent-warns-study 2024-10-27T16:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/0ae53e7494f0b9a3/apellis-sobi-announced-results-from-phase-3-valiant-study-markets-insider 2024-10-27T16:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/9e581a0969f50be4/nonopioid-medication-overuse-headache-remission-observed-with-erenumab 2024-10-27T16:12:17+00:00 weekly 0.7 https://trial.medpath.com/news/2a256a8e47661f24/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-globenewswire 2024-10-27T16:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/f237fc7b96dd59a3/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/4090af7ee11c8ffe/positive-trial-results-for-pyc-s-eye-disease-therapies-sharecafe 2024-10-27T15:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/c33a5227d0a1949a/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/70c8174e98f4e98d/new-trial-shows-felzartamab-reduces-proteinuria-in-iga-nephropathy-patients 2024-10-27T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/ba0a340666fa7539/weekend-icymi-october-21-to-october-25-drug-topics 2024-10-27T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/caa487c751d577db/what-experts-say-about-taking-psilocybin-as-an-alternative-treatment-for-depression-wxow 2024-10-27T14:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/f4c0eaaca9262792/catalyst-orthoscience-receives-fda-510-k-clearance-of-proximal-humerus-fracture-system 2024-10-27T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/21302c6146b39792/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T13:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/4e715a80724bcab5/carla-nester-md-pegcetacoplan-in-c3-glomerulopathy-and-primary-ic-mpgn-hcplive 2024-10-27T13:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/ed6c9e5b774aa801/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/f7da641924c23dad/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/22f07b9ce8429fa8/jspr-jasper-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/f0bb58cfb490eba7/with-92m-kivu-sets-out-to-make-kinder-gentler-adcs-biopharma-dive 2024-10-27T12:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/eede38c5606962d5/apellis-sobi-announced-results-from-phase-3-valiant-study-tipranks-com 2024-10-27T12:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/21d02ed4932b4b8c/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-quantisnow 2024-10-27T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/d71afd6e985461b7/vera-therapeutics-announces-96-week-egfr-stabilization-in-globenewswire 2024-10-27T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/daaaff42bb0fbae6/diabetes-drug-semaglutide-may-reduce-kidney-damage-study-finds-the-express-tribune 2024-10-27T11:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/5e2d1ac497e713ad/a-multipronged-approach-can-address-disparities-in-cancer-care-for-patients-in-rural-communities 2024-10-27T11:19:31+00:00 weekly 0.7 https://trial.medpath.com/news/1aa820b805c00c9a/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T10:26:32+00:00 weekly 0.7 https://trial.medpath.com/news/2323fd8073dab668/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T10:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/0279943208f3000b/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical 2024-10-27T10:13:02+00:00 weekly 0.7 https://trial.medpath.com/news/f79593d5666daf2d/dr-panken-discusses-study-evaluating-trt-and-atrial-fibrillation-acute-kidney-injury 2024-10-27T10:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/472d70045bf13617/uconn-professors-are-working-to-treat-pain-without-opioids-shelton-herald 2024-10-27T09:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/2c51e118d4e13719/arovella-receives-r-d-tax-incentive-and-new-advisory-board-finance-news-network 2024-10-27T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/12596741f5839684/rocatinlimab-improves-scorad-in-adults-with-moderate-to-severe-ad 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/fb8e25fdf2b96826/long-term-results-demonstrate-clinically-meaningful-improvements-in-hair-regrowth 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/142dd88537eb3816/pressr-kfshrc-advances-clinical-trials-through-strategic-partnerships-tradingview 2024-10-27T08:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/f4def0770695aa65/echo-iq-secures-fda-clearance-for-ai-software-finance-news-network 2024-10-27T07:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/26d822c9acf1c6fc/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-2 2024-10-27T07:35:12+00:00 weekly 0.7 https://trial.medpath.com/news/6308e25ffe4d61c3/trial-assesses-antibody-therapy-for-chronic-a-eurekalert 2024-10-27T07:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/1b8c86129145dce0/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-27T06:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/e47b5558ed888e6c/semaglutide-shows-benefit-in-ckd-and-type-2-diabetes-across-kidney-disease-severities 2024-10-27T06:20:02+00:00 weekly 0.7 https://trial.medpath.com/news/ec29a679d46f33b0/valiant-pegcetacoplan-offers-benefit-for-upcr-egfr-c3-staining-in-c3g-ic-mpgn 2024-10-27T06:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/adef339fa5c716e4/pbm-payment-disparities-threaten-independent-pharmacies-chain-stores-receive-up-to-15x-higher-reimbursements 2024-10-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a0b7cb3d8700d420/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/7679f333d8c6a5a2/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-globenewswire 2024-10-27T05:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/68beae8d3c4032f7/adcs-may-change-the-landscape-of-her2-mutant-nsclc-oncology-nursing-news 2024-10-27T05:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/6d6a673db9329061/vera-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T04:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/2e10b33846965aa0/depagliflozin-lowers-risk-of-decline-in-late-stage-kidney-disease-hcplive 2024-10-27T04:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/9eca2a0e67666ec9/final-ecztend-study-results-confirm-long-term-safety-and-efficacy-of-tralokinumab-for 2024-10-27T04:02:30+00:00 weekly 0.7 https://trial.medpath.com/news/547ecf31b8fed24d/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T04:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/dbe9d804aeea624d/apple-s-airpods-as-hearing-aids-a-step-forward-in-hearing-loss-care-but-barriers-remain 2024-10-27T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe9e727b8bd0c781/investigational-nipocalimab-demonstrates-efficacy-and-safety-in-adolescent-population-of 2024-10-27T03:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/3b92ada09c6ecf9f/how-ozempic-could-cure-common-leg-problem-one-in-ten-women-suffer-as-some-say-nhs 2024-10-27T02:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/ecdfd1ca21b21053/lebrikizumab-demonstrates-efficacy-in-itch-and-skin-clearance-among-patients-with-ad 2024-10-27T02:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/2a63faaecc8400d8/richard-pratley-md-flow-mortality-data-and-allocation-strategies-for-semaglutide 2024-10-27T01:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/cb8e68fc98845ae9/advanced-nanotherapies-announces-positive-results-in-its-first-in 2024-10-27T01:12:37+00:00 weekly 0.7 https://trial.medpath.com/news/a68f0d6a455489ae/day-3-recap-fall-clinical-2024-dermatology-times 2024-10-27T01:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/0a3db75ef9ab30d8/pediatric-febrile-uti-may-hurt-kidney-function-medpage-today 2024-10-27T01:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/cb741f12c77fd92a/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/25d01306ec78f39e/icu-seastar-medical-holding-corporation-latest-stock-news-market-updates 2024-10-27T00:43:17+00:00 weekly 0.7 https://trial.medpath.com/news/6d14ab1f26e08f83/the-oncfive-top-oncology-articles-for-the-week-of-10-20-onclive 2024-10-27T00:32:35+00:00 weekly 0.7 https://trial.medpath.com/news/3d2479ab53d13205/novartis-pharma-ag-globenewswire 2024-10-27T00:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/aa39b08e474248d4/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/37d97623570f758d/kidney-compass-atacicept-for-igan-with-jonathan-barratt-phd-at-kidney-week-2024 2024-10-27T00:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/a1ea2886902d8ce2/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T00:18:37+00:00 weekly 0.7 https://trial.medpath.com/news/6395d77cfc5fbc5f/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-26T23:54:33+00:00 weekly 0.7 https://trial.medpath.com/news/83a7b1e1a6590c5b/clinical-trials-yield-promising-kidney-health-results-mirage-news 2024-10-26T23:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/a7447825663be5f1/travere-therapeutics-presents-data-reinforcing-clinical-benefit-of-filspari-r-sparsentan 2024-10-26T23:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/808b1cdd19235b4c/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-first 2024-10-26T23:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/cf2948782a9e6c60/analysis-shows-perioperative-pembrolizumab-efficacy-in-nsclc-targeted-oncology 2024-10-26T23:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/4f1595176c934c22/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-26T22:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/25446b30a8bef961/the-european-medicines-agency-approved-the-first-anti-coronavirus-pill-telegrafi 2024-10-26T22:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/8a4ffc140486b869/alternative-pathway-inhibition-makes-good-in-iga-nephropathy-medpage-today 2024-10-26T21:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/ca5ad1ed0c09dabc/celldex-announces-barzolvolimab-met-all-primary-and-globenewswire 2024-10-26T21:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/cd759b7937d9fdbc/ringer-s-lactate-administered-at-15-degc-leads-to-a-greater-and-more-prolonged-increase-in 2024-10-26T21:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/ce50b533e8652e24/spyre-therapeutics-catalyst-cascade-on-track-for-late-2024-rttnews 2024-10-26T20:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/91390ec8a3773c12/novartis-ribociclib-recognized-as-category-1-preferred-breast-cancer-adjuvant-treatment-by 2024-10-26T20:29:26+00:00 weekly 0.7 https://trial.medpath.com/news/8d738ed636295c1b/hope-for-a-revolution-in-treatment-for-severe-burns-victims-sbs-news 2024-10-26T20:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/b6125e086531d9ba/5-fluorouracil-combined-with-callisphere-drug-eluting-beads-or-conventional-transarterial-nature 2024-10-26T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/947357bd80fc3fcf/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T19:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/1b819eab2957a166/patients-taking-ozempic-are-up-to-70-percent-less-likely-to-develop-alzheimer-s-research-finds 2024-10-26T19:36:24+00:00 weekly 0.7 https://trial.medpath.com/news/a2d2d337553d45c2/semaglutide-linked-to-reduced-albuminuria-for-adults-with-ckd-without-diabetes-healio 2024-10-26T19:21:01+00:00 weekly 0.7 https://trial.medpath.com/news/ccd36b3fe0a5f9e3/efficiency-of-multivariate-tests-in-trials-in-progressive-supranuclear-palsy-nature 2024-10-26T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/794d21ac173e7835/shawn-kwatra-md-making-the-connection-between-prurigo-nodularis-atopic-dermatitis-and-itch 2024-10-26T18:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/60ca09f82487f1be/stockwatch-sangamo-shares-surge-on-shorter-pathway-for-fabry-candidate 2024-10-26T18:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/9a91ce92d7494d44/pivotal-valiant-results-presented-at-kidney-week-show-pegcetacoplan-treatment-effect-in-sobi 2024-10-26T18:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/a20bf0401a1128e8/behind-the-ecog-acrin-e1910-trial-blinatumomab-in-b-all-targeted-oncology 2024-10-26T18:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/5cf3620e58a1176b/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T18:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/8491177ff52521dd/jennifer-lai-yee-md-phd-mph-honing-in-on-sparsentan-s-benefit-in-genetic-fsgs 2024-10-26T17:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/d613efe9595cc118/mhra-greenlights-donanemab-for-early-stage-alzheimer-s-disease-news-medical 2024-10-26T17:29:07+00:00 weekly 0.7 https://trial.medpath.com/news/cc4366a6d26291fe/phase-3-program-of-vidofludimus-calcium-continues-chmp-recommends-approval-for 2024-10-26T17:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/de6f1897e7754c00/travere-therapeutics-presents-data-reinforcing-clinical-globenewswire 2024-10-26T17:02:28+00:00 weekly 0.7 https://trial.medpath.com/news/f1634b0911f1315e/fighting-triple-negative-breast-cancer-is-hard-but-not-impossible 2024-10-26T16:39:57+00:00 weekly 0.7 https://trial.medpath.com/news/207c0a9be60fc146/kat-aki-tailored-ehr-alerts-fail-to-improve-aki-management-in-hospitalized-patients 2024-10-26T16:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/e930333e8e2e7439/disc-medicine-presents-positive-data-from-sad-cohorts-of-a-phase-1b-trial-in-patients-with 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/9f63b312bbd97ea4/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-biospace 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/38dd2fdb59acc311/kind-announces-fda-granted-orphan-drug-designation-odd-for-and017-in-the-biospace 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/4e55ee4d40eb0735/evecxia-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-the-fda 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/b60a2ba274f0ee57/vertex-provides-updates-on-multiple-kidney-programs-at-the-american-society-of-biospace 2024-10-26T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/4d0bd34b96de50b4/precision-medicine-approach-shows-promise-for-anaplastic-thyroid-cancer-medpage-today 2024-10-26T15:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/5bae64b05dccbfbc/top-5-infectious-disease-news-stories-week-of-october-18-25-contagion-live 2024-10-26T15:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/bd6aa7cfa9ff5d95/driving-pressure-during-general-anesthesia-for-minimally-invasive-abdominal-surgery-generator 2024-10-26T14:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/b98d392544d50cbf/evaluating-immunotherapy-options-based-on-mutations-for-nsclc-cancer-network 2024-10-26T14:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/b687877f58ba71ab/day-2-recap-fall-clinical-2024-dermatology-times 2024-10-26T14:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/25749efce9201900/upadacitinib-shows-long-term-benefits-in-teens-with-atopic-dermatitis-medpage-today 2024-10-26T13:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/25bd03fa4e7b9c3a/semaglutide-shows-promise-reduces-uacr-in-nondiabetic-kidney-disease-hcplive 2024-10-26T13:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/3efe9728142b35d4/stx-478-may-improve-therapeutic-index-vs-other-pi3k-inhibitors-in-cancer 2024-10-26T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/7104a6b34eb003ff/go-fgfr-tyra-s-urothelial-data-upbeat-stock-down-bioworld 2024-10-26T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/065a9d0b46f61f75/september-conferences-deliver-wave-of-positive-clinical-updates-bioworld 2024-10-26T13:10:10+00:00 weekly 0.7 https://trial.medpath.com/news/2c02f19ad0f35ed9/available-therapeutics-and-upcoming-advancements-in-atopic-dermatitis-and-prurigo-nodularis 2024-10-26T13:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/86a4b12d7dfe6227/new-phase-3b-findings-suggest-lebrikizumab-improved-skin-itch-for-atopic-dermatitis 2024-10-26T12:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/87647dba1aa91fa9/empagliflozin-benefits-on-kidney-disease-progression-death-continue-for-1-year-post 2024-10-26T12:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/71a0c5d624691a22/sanofi-to-present-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-26T12:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/19bb06a1c8b89b04/pharmacist-prescribed-birth-control-emerges-as-key-solution-to-address-u-s-maternal-health-deserts 2024-10-26T12:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/91304ae422b536f3/will-herrington-mbbs-md-ma-empagliflozin-follow-up-data-informs-clinical-care-for-ckd 2024-10-26T12:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/edd52605411c5609/what-happened-in-optometry-this-week-october-21-october-25 2024-10-26T11:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/e2a2d5805539aa6f/and017-receives-fda-orphan-drug-designation-for-sickle-cell-disease-hcplive 2024-10-26T11:30:37+00:00 weekly 0.7 https://trial.medpath.com/news/414a0cf917f85caf/medtronic-receives-us-fda-approval-for-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-26T11:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/fd799dd889618736/pioneering-trial-to-test-multiple-new-treatments-for-glioblastoma-news-medical 2024-10-26T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/8a8458b90f0efb01/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-1 2024-10-26T10:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/46549e513d6307eb/pharma-stock-roundup-rhhby-earnings-drug-pipeline-regulatory-news 2024-10-26T09:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/2911726ffaee1e7d/fda-accepts-new-drug-application-for-pixclara-for-glioma-imaging-cure-today 2024-10-26T09:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/6eb8b1730adfb867/community-pharmacies-urged-to-adopt-clinical-program-mindset-for-service-expansion 2024-10-26T08:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/7d26d76cd2cf2952/leveraging-ai-to-optimize-precision-immunotherapy-at-vanderbilt 2024-10-26T08:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/a3d1c3c54b5aa178/the-wee1-inhibitor-apr-1051-shows-early-safety-and-tolerability-in-advanced-mutated 2024-10-26T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/ff374ff1941f9439/biogen-stock-hits-52-week-low-at-181-25-amid-market-challenges-investing-com 2024-10-26T08:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/d1a0999a4e11470f/2024-2025-respiratory-vaccine-guidelines-key-updates-for-covid-19-flu-rsv-and-pneumococcal-vaccines 2024-10-26T08:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/4452a3a31a6fe966/swedish-studies-show-rising-cancer-rates-during-pregnancy-but-favorable-outcomes-for-breast-cancer-patients 2024-10-26T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a49aca6f867be1df/epinephrine-film-offers-oral-allergy-relief-in-few-minutes-study-allergic-living 2024-10-26T07:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/d074c51c814d5dbb/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-26T07:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/a15a2fed2d60ad78/fda-grants-orphan-drug-designation-to-mdl-101-for-congenital-muscular-dystrophy-type-1a 2024-10-26T07:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/eb2fd907e57b2d02/cgtlive-r-s-weekly-rewind-october-25-2024 2024-10-26T07:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/0ddf70cfca388640/abbvie-gedeon-richter-ink-deal-to-develop-novel-targets-for-neuropsychiatric-conditions 2024-10-26T06:36:51+00:00 weekly 0.7 https://trial.medpath.com/news/89f2293057883f1f/zaltenibart-receives-fda-rare-pediatric-disease-designation-for-c3-glomerulopathy 2024-10-26T06:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/e07b81e63808a7c3/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials-jd-supra 2024-10-26T06:19:22+00:00 weekly 0.7 https://trial.medpath.com/news/b26a7d351c6c1e58/liquid-biopsy-imaging-may-show-benefit-in-li-fraumeni-syndrome-screening 2024-10-26T06:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/132037bb71334d58/ribociclib-recognized-by-nccn-clinical-practice-guidelines-as-category-1-pharmacy-times 2024-10-26T06:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/d5960f6f7990eb45/trial-highlights-potential-next-gen-biologic-for-lung-cancer 2024-10-26T05:26:44+00:00 weekly 0.7 https://trial.medpath.com/news/a49ece168b831d5a/semaglutide-may-reduce-alzheimer-s-risk-in-diabetics-news-medical 2024-10-26T05:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/a26b2a8cb66f256d/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical-significance-in-positive-phase-2-study-in-chronic-inducible-urticaria 2024-10-26T05:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/36e300f294b530ab/psyence-group-expands-psilocybin-clinical-trials-tipranks-com 2024-10-26T04:16:19+00:00 weekly 0.7 https://trial.medpath.com/news/3de9d41ee66e98b9/leo-s-adbry-demonstrates-long-term-efficacy-in-atopic-dermatitis 2024-10-26T04:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/b8c3463573a87e42/dll3-targeted-adc-produces-responses-in-previously-treated-es-sclc 2024-10-26T04:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/edca6882d0a20cb1/new-study-shows-curcuma-based-nutritional-supplements-may-be-associated-with-the 2024-10-26T04:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/b8e826b396e71933/fda-approves-new-oral-antibiotic-orlynvah-for-uutis-investing-com-nigeria 2024-10-26T04:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/457ba6230291b191/tonix-pharmaceuticals-announces-submission-of-the-tnx-102-sl-new-drug-application 2024-10-26T03:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/7f1bce5201dc3a63/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-26T03:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/60edc43d361b3532/blockbuster-obesity-drugs-also-may-slow-kidney-disease-vumc-news 2024-10-26T03:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/42edb7a4b1f8256e/tms-for-the-treatment-of-ocd-psychiatric-times 2024-10-26T03:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/617ec9b566eb6227/sanofi-backed-agomab-raises-89m-to-advance-fibrotic-disease-treatments 2024-10-26T02:59:23+00:00 weekly 0.7 https://trial.medpath.com/news/026d57bac96b1751/nab-sirolimus-and-its-role-in-pecoma-treatment-targeted-oncology 2024-10-26T02:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/7acc01f9219d16b0/pancreatic-cancer-market-to-hit-us-11-5-billion-by-2033 2024-10-26T02:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/223450f38b203ebc/asthma-drug-does-not-speed-covid-19-recovery-study-vumc-news 2024-10-26T01:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/8ca14c48437a180a/nurse-led-discussion-on-diet-during-radiation-may-boost-quality-of-life-oncology-nursing-news 2024-10-26T01:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/098076ba38dc1cea/biopharma-operator-zai-lab-surges-to-16-month-high-on-lung-cancer-drug-trial-results 2024-10-26T00:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/4331468e68c54a27/new-phase-3-data-shows-high-rate-of-atopic-dermatitis-clearance-using-tapinarof-cream-1 2024-10-26T00:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/d9cdc33eeec1c5cd/optimistic-buy-rating-for-ideaya-biosciences-driven-by-promising-ide397-data-and-strong 2024-10-26T00:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/ef9529a2c95390ec/micurx-announces-the-successful-completion-of-phase-1-clinical-trial-of-mrx-5-in-australia 2024-10-25T23:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/b7bfd44a19a4f5c1/fabry-disease-gene-therapy-study-data-enough-for-fda-submission 2024-10-25T23:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/9c60c053f39f5d8c/genedx-reveals-new-findings-from-newborn-genetic-screening-study-clinical-trials-arena 2024-10-25T22:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/c83462db1a82c860/immunitybio-commences-cd19-t-hank-cell-therapy-trial-for-nhl 2024-10-25T22:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/c042d7e9392c94de/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv-biospace 2024-10-25T22:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/1d40d37820f43502/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T22:35:52+00:00 weekly 0.7 https://trial.medpath.com/news/ed2223b861d410d7/the-potential-of-device-assisted-therapies-in-pd-insights-from-the-phase-1-2-dive-i-trial 2024-10-25T22:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/10f55403ab596125/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-jd-supra 2024-10-25T22:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/e3d9be7b5b3c9211/medtronic-s-innovative-affera-system-gains-fda-approval-boosting-ep-market-prospects 2024-10-25T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/503f6bee981dc173/radicava-ors-slows-als-disease-progression-improves-survival-als-news-today 2024-10-25T21:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/e754821256a10dbe/hemophilia-a-b-prophylaxis-therapy-hympavzi-may-soon-be-available-in-us 2024-10-25T21:26:05+00:00 weekly 0.7 https://trial.medpath.com/news/ee478d6b656bc5ec/fda-approves-estradiol-gel-0-06-for-women-post-menopause-pharmacy-times 2024-10-25T21:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/020d608493e43f77/orexo-initiates-new-study-of-ox640-in-participants-with-allergic-rhiniti 2024-10-25T21:10:55+00:00 weekly 0.7 https://trial.medpath.com/news/54cc297b2f94b40c/fda-approves-orlynvah-sulopenem-etzadroxil-and-probenecid-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T21:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/06b137bdcb5dcd86/ani-pharmaceuticals-announces-fda-approval-of-estradiol-gel-0-06-markets-insider 2024-10-25T20:50:27+00:00 weekly 0.7 https://trial.medpath.com/news/4a28bc58b3aca62a/fda-approves-novel-treatment-for-utis-medpage-today 2024-10-25T20:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/3a17cfcfa41d50d7/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/9938b05af2ba0468/iterum-therapeutics-announces-fda-approval-of-orlynvah-markets-insider 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/60b6a80226e37b91/with-fda-approval-iterum-s-patience-pays-off-bioworld 2024-10-25T20:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/a7c99498ecaf6fdd/photonpharma-installs-new-ceo-as-ovarian-cancer-drug-trial-launches-bizwest 2024-10-25T20:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/a4a1c39406bce4b1/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T20:17:15+00:00 weekly 0.7 https://trial.medpath.com/news/0ab34c6be2b6a75d/regulatory-collaboration-on-mpox-treatments-summarized-in-report 2024-10-25T20:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/19a94ebb31075981/fda-approves-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T19:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/c7424c09949ff255/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-25T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/news/b3073f689583c6ae/qurient-launches-clinical-trial-for-acute-myeloid-leukemia-treatment-with-adrixetinib-q702 2024-10-25T19:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/d4799121c9ba6a0d/single-treatment-with-crispr-gene-editing-therapy-offers-hope-for-hereditary-angioedema-patients 2024-10-25T18:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/f29edb3476c16039/a-promising-candidate-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T18:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/337bc3a547612bd9/caris-life-sciences-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-25T18:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/74703bb0c0ea08fc/immunotherapy-combinations-dominate-frontline-discussions-in-advanced-rcc-onclive 2024-10-25T18:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/f164c2820a3d3a84/fda-approves-oral-sulopenem-orlynvah-for-uncomplicated-urinary-tract-infections 2024-10-25T18:22:13+00:00 weekly 0.7 https://trial.medpath.com/news/049edcc3e1cd3fc7/pipettes-take-small-molecule-inhibitors-from-discovery-to-clinical-trials-selectscience 2024-10-25T18:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/9e2b860d41f444cf/eli-lilly-s-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously 2024-10-25T18:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/342f795cf800b99a/nivolumab-plus-avd-prolongs-pfs-vs-brentuximab-vedotin-plus-avd-in-advanced-stage 2024-10-25T18:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/f422467fb4d81219/can-a-kidney-action-team-improve-patient-outcomes-yale-school-of-medicine 2024-10-25T18:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/25b3ed4275b0c814/first-patient-dosed-in-phase-3-lugano-trial-of-duravyu-for-wet-amd-healio 2024-10-25T18:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/e10cc64e9a875e6e/ultimovacs-asa-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T17:53:50+00:00 weekly 0.7 https://trial.medpath.com/news/5c157a64910a98a2/fda-approves-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/d5f5be9aa6fb3b27/fda-approves-oral-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/653ba4b30c341afb/fda-approves-medtronic-s-new-all-in-one-mapping-and-ablation-system-for-afib 2024-10-25T17:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/08b69256e99fbb3d/fda-approves-mapping-dual-energy-catheter-ablation-system-for-persistent-af-healio 2024-10-25T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/97edc88af08f12ef/could-ozempic-lower-the-risk-of-alzheimer-s-newsnation 2024-10-25T17:24:23+00:00 weekly 0.7 https://trial.medpath.com/news/7e42f131015bed21/medtronic-receives-us-fda-approval-of-affera-mapping-and-ablation-system-and-sphere-9-catheter 2024-10-25T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/831d6253509d27ac/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T17:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/7db83ca349622537/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-yahoo-finance 2024-10-25T17:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/d52d579e1e019a74/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3 2024-10-25T16:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/ba3ecaced8fb0367/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T16:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/8679dc3e1968698d/eisai-never-told-patients-in-leqembi-clinical-trials-they-faced-higher-risk-of-brain-bleeds 2024-10-25T16:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/5668617ca817c380/fda-approves-oral-sulopenem-for-uncomplicated-urinary-tract-infection-urology-times 2024-10-25T16:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/f61a51f6e6ba783a/iterum-therapeutics-shares-soar-on-fda-s-orlynvah-approval-morningstar 2024-10-25T16:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/63a72c017d5e41cf/fda-approves-oral-sulopenem-for-treatment-of-uncomplicated-utis-contemporary-ob-gyn 2024-10-25T16:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/d4a5fe02b535d046/jubilant-therapeutics-announces-first-patient-dosing-in-global-clinical-trials-for-jbi-802-and-jbi-778 2024-10-25T16:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/87bdf5118968001c/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-medtech-dive 2024-10-25T16:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/c2782dc24e708b44/criteriamapper-establishing-the-automatic-identification-of-clinical-trial-cohorts-from-nature 2024-10-25T16:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/92e0acc138aa403b/mdma-therapy-for-mental-health-conditions-do-the-benefits-outweigh-the-risks 2024-10-25T16:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/f61c671506529fb6/a-potential-first-in-class-selective-ck1a-molecular-glue-degrader 2024-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a27b3896fc4fcfbd/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-recruitment 2024-10-25T15:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/ec7e33d5718d1705/maze-therapeutics-reports-positive-first-in-human-data-from-phase-1-healthy-volunteer 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/10d5c2af6c1d3099/leo-pharma-presents-final-results-of-ecztend-long-term-adbry-r-trial-tralokinumab 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/410d9739b92b78eb/genomics-series-navigating-regulatory-challenges-in-the-era-of-cell-and-gene-therapies 2024-10-25T15:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/491d35da743594c0/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T15:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/deb86ccc0036cfa8/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines 2024-10-25T15:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/cc9eefa82204f956/second-alzheimer-s-drug-rejected-by-nice-on-the-same-day-it-is-approved-in-the-uk 2024-10-25T15:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/b09804c0737bc639/teva-mabxience-expand-partnership-for-additional-oncology-biosimilar-candidate 2024-10-25T15:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/a786387d866d40d7/eligible-infants-included-in-neonatal-clinical-trials-and-reasons-for-noninclusion 2024-10-25T15:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/879ae4f1814ee17b/cadonilimab-is-effective-and-safe-in-recurrent-cervical-cancer-nature-reviews-clinical-oncology 2024-10-25T15:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/463da17c975e89da/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-globenewswire 2024-10-25T15:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/af236c080ad0d092/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T15:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/be6880bf8ec2c8f7/fda-approves-novel-schizophrenia-drug-psychiatry-and-behavioral-health-jama-network 2024-10-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf1aa9af7abca095/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae-yahoo-finance 2024-10-25T15:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/37d6eeb07f194d43/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T15:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/14b4a5ce78daa2ec/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae 2024-10-25T14:49:23+00:00 weekly 0.7 https://trial.medpath.com/news/7c543cd79e7f9ea0/gsk-invests-800m-in-manufacturing-amgen-sets-small-discount-for-eylea-biosimilar 2024-10-25T14:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/49057cf2d98e3f81/young-adult-breast-cancer-survivor-why-i-joined-a-clinical-trial-at-md-anderson 2024-10-25T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/f11ee520ac6850c4/weight-management-market-continues-to-grow-benefits-and-pensions-monitor 2024-10-25T14:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/3f9d2c984ff7434f/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-25T14:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/508d323886d6c4b0/fda-approves-pfizer-s-rsv-vax-abrysvo-in-adults-at-increased-risk-contract-pharma 2024-10-25T14:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/fd7c6b537be76e94/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-biospace 2024-10-25T14:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/c7e5694ef10b7b0d/psyence-group-s-nasdaq-listed-associate-psyence-globenewswire 2024-10-25T13:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/3de5a80200613092/lakeshore-biopharma-s-ysja-rabies-vaccine-heads-to-phase-iii-trial-contract-pharma 2024-10-25T13:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/ed4a81a0dde5923c/farrsight-twin-technology-transforms-cancer-treatment-research-news-medical 2024-10-25T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/59e006521a43c267/pa-psychedelic-bulletin-178-va-funding-of-lykos-phase-3-definitely-a-possibility 2024-10-25T13:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/f436036c9c91880d/a-potential-first-in-class-ent1-inhibitor-for-immuno-oncology-indications-derived-from-dilazep 2024-10-25T13:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/df74c9f0ba77a365/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials 2024-10-25T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/df936fbb339c1461/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-25T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/4b299e62dfbe06b4/polestar-results-show-pfs-benefit-of-aumolertinib-in-nsclc-targeted-oncology 2024-10-25T13:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/e933dc04559d8bf1/intellia-s-crispr-gene-editor-cuts-hereditary-angioedema-attacks-by-81-in-phase-ii-study 2024-10-25T12:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/22a60fa3bdbc4214/bioduro-sundia-expands-shanghai-operations-with-new-kilogram-laboratory-and-compound-management-center 2024-10-25T12:50:15+00:00 weekly 0.7 https://trial.medpath.com/news/ac8d6ae2e495ce75/cannabis-medicine-trials-for-refractory-epilepsy-to-start-in-2025 2024-10-25T12:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/3ae8d1596734ca13/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-stock-titan 2024-10-25T12:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/00b7f0b6b1b07f48/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-quantisnow 2024-10-25T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/6068e4c0b4dd6911/mindmed-to-lead-first-lsd-phase-3-trials-for-anxiety-drug-discovery-and-development 2024-10-25T12:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/2a484293ac37b6b6/lakeshore-s-ysja-rabies-vaccine-receives-approval-for-phase-iii-trial-in-china-tipranks 2024-10-25T12:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/52d9df71f9d39e31/liquid-biopsy-advances-transform-mrd-detection-in-high-risk-breast-cancer-management 2024-10-25T12:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/cc518e791a7663d9/mapping-drug-resistance-variants-in-cancer-one-base-at-a-time-nature-genetics 2024-10-25T12:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/ee449351a453b4af/admare-bionnovations-cancer-research-uk-and-kisoji-biotechnology-collaborate-to 2024-10-25T12:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/fd7289c6516a809f/post-hoc-analysis-of-essence-1-trial-highlights-efficacy-of-0-1-cyclosporine-solution-for 2024-10-25T12:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/08d068f048b69344/pet-imaging-agent-earns-fda-priority-review-in-recurrent-glioma-cancer-network 2024-10-25T12:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/d298c229423a46c6/future-clinical-trials-sequencing-decisions-for-bispecifics-and-car-t-cell-therapy 2024-10-25T12:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/f2bda8d0899cc0eb/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T11:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/9b3d41343692dccf/alkeus-pharmaceuticals-announces-topline-results-from-saga-trial-on-ga-treatment 2024-10-25T11:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/2968640896c01f86/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3-medical-device-network 2024-10-25T11:38:46+00:00 weekly 0.7 https://trial.medpath.com/news/9c99f83ebd5d0b3f/protalix-biotherapeutics-to-present-phase-i-prx-115-data-in-late-breaking-poster-at-acr 2024-10-25T11:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/8f3f2513d7daf969/marinus-clinical-trial-of-ganaxolone-fails-to-meet-primary-endpoint-yahoo-finance 2024-10-25T11:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/7756d928f537006d/invitation-sobi-s-aspaveli-r-and-the-phase-3-valiant-data-in-nephrology-call 2024-10-25T11:33:53+00:00 weekly 0.7 https://trial.medpath.com/news/65446d879e23e7c9/a-first-in-class-targeted-therapy-for-some-gastrointestinal-cancers 2024-10-25T11:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/cd5ba151c30833e4/positive-pipeline-updates-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T11:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/3adbe71d03de6589/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials-for-jbi 2024-10-25T11:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/087194c5f9bbcc02/impact-biotech-to-present-updated-interim-phase-3-data-from-globenewswire 2024-10-25T11:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/64ca96087eea2a6a/sonara-health-rolls-out-remote-monitoring-app-to-tackle-methadone-drop-out 2024-10-25T11:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/104f165d54047f6a/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T10:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/2e11366382bb5e51/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:57:25+00:00 weekly 0.7 https://trial.medpath.com/news/33cbdf7ab227e832/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/8a8364dfc7b2a4b1/digital-twins-of-cancer-patients-predict-effectiveness-of-treatments-the-engineer 2024-10-25T10:46:23+00:00 weekly 0.7 https://trial.medpath.com/news/6b702c29ef0c51e0/fda-approves-medtronic-s-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-25T10:43:27+00:00 weekly 0.7 https://trial.medpath.com/news/c8294d4035e6c3b7/eyepoint-stock-gains-traction-with-new-amd-trials-jefferies-sees-65-upside-investing-com 2024-10-25T10:38:08+00:00 weekly 0.7 https://trial.medpath.com/news/093ae21eb064bb03/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-globaldata 2024-10-25T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/238b1badc83a8d85/assessing-the-impact-of-immersive-virtual-reality-technology-on-the-psychological-recovery-trials 2024-10-25T10:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/ce86b7f67095433f/what-works-best-to-ease-ms-linked-fatigue-new-study-finds-out 2024-10-25T10:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/35da835c923dabeb/are-elimination-diets-much-help-against-child-eczema 2024-10-25T10:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/15bdce7f9371a759/modalis-therapeutics-has-received-an-orphan-drug-designation-from-the-u-s-food-and 2024-10-25T10:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/ebd6a0972f13a9ba/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-25T10:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/2448b5bfd716f96d/novocure-s-wearable-device-receives-fda-approval-for-metastatic-cancer-treatment 2024-10-25T09:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/9951e87dc53de340/kymera-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-trial-of-kt 2024-10-25T09:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/353bd495923fe73f/ocugen-gets-green-light-to-move-onto-phase-2-portion-of-trial-evaluating-stargardt-gene 2024-10-25T09:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/6b3b9a606a45af5c/ozempic-linked-with-lower-risk-of-alzheimer-s-diagnosis-medpage-today 2024-10-25T09:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/fe9434426f4bb922/vaccinex-to-report-promising-new-efficacy-data-for-signal-ad-phase-1b-2-trial-of-biospace 2024-10-25T09:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/8d6b6d73f702ce16/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-25T09:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/9c348aa4ec80e05b/aquestive-therapeutics-announces-positive-topline-results-from-oral-allergy-syndrome 2024-10-25T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/48a23b4b2a2d573a/intermittent-versus-continuous-calorie-restriction-for-treatment-of-metabolic-dysfunction-pubmed 2024-10-25T08:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/b071372c7599a38f/dexcom-submits-15-day-cgm-to-fda-stock-sinks-after-hours-despite-street-beating-q3 2024-10-25T08:29:36+00:00 weekly 0.7 https://trial.medpath.com/news/2e67686e35bf084f/reporting-clinical-trial-results-to-the-market-taylor-wessing 2024-10-25T08:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/5eb13ddfc5628da7/multidisciplinary-collaboration-and-biomarker-testing-reshape-early-stage-lung-cancer-care 2024-10-25T08:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/b1070091a37c4687/lilly-s-donanemab-could-bring-new-hope-to-alzheimer-s-patients-in-australia-following 2024-10-25T08:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/b06a88c8478e33a9/founder-of-hua-medicine-dr-chen-li-was-awarded-the-c-c-tan-life-science 2024-10-25T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/ad1edf2a316fe646/multi-center-study-validates-safety-and-efficacy-of-senhance-robotic-system-in-colorectal-surgery 2024-10-25T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/467d1443ba4abeae/scientists-create-cancer-patients-digital-twins-to-predict-how-well-treatments-may-work 2024-10-25T07:48:27+00:00 weekly 0.7 https://trial.medpath.com/news/03cc1f9166559ff4/press-release-sanofi-q3-15-7-sales-growth-boosted-by-earlier-than-anticipated-vaccine-sales 2024-10-25T07:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/ae8666c16f3e2c17/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients 2024-10-25T07:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/4b3a560a86e89814/clarametyx-biosciences-initiates-phase-2a-trial-for-cmtx-101-in-cystic-fibrosis-patients 2024-10-25T07:12:37+00:00 weekly 0.7 https://trial.medpath.com/news/6eb1bfe58a792e61/miami-cancer-institute-launches-innovative-app-fellowship-for-hematology-and-bone-marrow-transplant-care 2024-10-25T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/405097898d548bc6/promising-phase-ii-results-and-market-potential-support-buy-rating-for-intellia-therapeutics 2024-10-25T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/news/3167578f0c3dd95e/olanzapine-and-cannabis-can-help-manage-nausea-during-chemotherapy 2024-10-25T06:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/c8bcff2abc152db1/regeneron-sanofi-announce-presentation-of-dupixent-phase-3-data-in-csu 2024-10-25T05:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/0bbb423e065dd2f5/stripe-initiative-advances-pharmacogenetic-testing-standards-with-focus-on-dpyd-guided-chemotherapy 2024-10-25T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/3e7283e06f392887/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-says-globaldata 2024-10-25T04:31:09+00:00 weekly 0.7 https://trial.medpath.com/news/966674c9816a19c5/abbott-kicks-off-new-trial-aiming-to-improve-heart-failure-outcomes-with-cardiomems-heartmate-3 2024-10-25T03:32:36+00:00 weekly 0.7 https://trial.medpath.com/news/21845a0cce7784d0/cultural-adaptation-and-flexibility-key-to-improving-diversity-in-diabetes-clinical-trials 2024-10-25T03:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/1708a9d42e9c4945/cotton-o-neil-marks-20-years-of-focused-clinical-research-program-wibw 2024-10-25T03:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/08742024af527011/medtronic-gets-fda-approval-for-affera-technology-morningstar 2024-10-25T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/8503bec28f776fd9/duchenne-muscular-dystrophy-dmd-pipeline-analysis-2024-openpr-com 2024-10-25T03:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/3d8923308ef5fb70/novartis-ribociclib-kisqali-r-recognized-as-category-1-preferred-breast-cancer-adjuvant 2024-10-25T02:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/6f2bd1760c78f4ee/digital-twin-could-help-predict-how-well-cancer-treatments-may-work-scimex 2024-10-25T01:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/f2bcdf410a245abc/naya-biosciences-announces-initiation-of-phase-1-2a-globenewswire 2024-10-25T01:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/5219052764a23f6e/abbott-launches-clinical-trial-to-optimize-heart-failure-treatment-hit-consultant 2024-10-25T00:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/babb7dca6ac04b91/the-impact-of-fdora-on-clinical-trial-diversity 2024-10-25T00:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/0292b16f62ff4494/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T00:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/41671778bc947076/metsera-reports-highly-competitive-results-from-ongoing-biospace 2024-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adf573eeea7b6370/clinical-trial-to-test-engineered-skin-for-severe-burns-starts-in-melbourne-s-alfred-hospital 2024-10-24T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/e67bee4b087886b1/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for-treatment-of-c3-glomerulopathy 2024-10-24T23:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/20c51ccdceea84ac/adjuvant-ribociclib-revamps-hr-her2-breast-cancer-management-onclive 2024-10-24T23:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/863d7952e6ef553d/dr-ma-on-interim-efficacy-and-safety-data-with-rly-2608-in-pi3ka-mutant-hr-her2 2024-10-24T23:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/d108e99df5b851ba/sbrt-vs-conventional-radiotherapy-for-localized-prostate-cancer-the-asco-post 2024-10-24T22:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/a1bb2d68b653bfb4/intellia-moves-into-phase-iii-with-ntla-2002-but-concerns-remain-scrip 2024-10-24T22:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/87d3fd381447fd01/fda-approves-medtronic-s-affera-sphere-9-for-cardiac-ablation-massdevice 2024-10-24T21:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/9e56434d0ebbf86b/gene-editing-therapy-reduced-attacks-in-hereditary-angioedema-medpage-today 2024-10-24T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/34b6ebf4f59528e2/onward-raises-54m-to-continue-neuromodulation-trials-clinical-trials-arena 2024-10-24T21:05:37+00:00 weekly 0.7 https://trial.medpath.com/news/ec7745e309bd5568/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/db64bfeb1c9f45d0/robotic-system-flags-potential-arrhythmia-therapies-inside-precision-medicine 2024-10-24T20:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/e628e768068283e4/cervical-dystonia-pipeline-assessment-2024-comprehensive-openpr-com 2024-10-24T20:44:17+00:00 weekly 0.7 https://trial.medpath.com/news/224d32528affb09c/recon-novo-nordisk-asks-fda-to-block-semaglutide-compounding-lilly-to-launch-obesity-raps 2024-10-24T20:42:55+00:00 weekly 0.7 https://trial.medpath.com/news/e53eb944fce9dc63/a-new-paradigm-in-electrophysiology-medtronic-receives-fda-approval-of-afferatm-mapping 2024-10-24T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/a65a2b1a3f94a249/medtronic-receives-fda-approval-of-afferatm-mapping-and-ablation-system-and-sphere-9tm-catheter 2024-10-24T20:34:21+00:00 weekly 0.7 https://trial.medpath.com/news/28a5b21a38384d53/local-patients-contribute-to-fda-approval-of-early-breast-cancer-drug-ksnv 2024-10-24T20:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/f4e53385e577c95f/dr-anne-marie-morse-on-the-significance-of-the-fda-s-approval-of-lumryz-for-pediatric-patients 2024-10-24T20:20:50+00:00 weekly 0.7 https://trial.medpath.com/news/7f6a6182661070e1/fda-approves-abbvie-therapy-for-adults-with-advanced-parkinson-s-disease-pharmtech 2024-10-24T20:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/22233b74c24296c7/dr-patel-on-findings-from-the-trust-ii-trial-in-ros1-nsclc-onclive 2024-10-24T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/6de784e5c4d7f872/fda-grants-priority-review-to-tlx101-cdx-for-glioma-imaging-onclive 2024-10-24T19:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/af144258eba035ff/first-patients-dosed-in-phase-1-clinical-study-of-immunitybio-s-car-nk-cell-therapy-for-the 2024-10-24T19:52:17+00:00 weekly 0.7 https://trial.medpath.com/news/d5cbda6b193fbdb4/toronto-firefighter-back-on-the-job-after-new-drug-slows-incurable-brain-cancer 2024-10-24T19:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/5d3df3fc748608f8/us-fda-approves-nda-for-lenz-therapeutics-lnz100-for-the-treatment-of-presbyopia 2024-10-24T19:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/4bfa02abfd7aaa40/marinus-pharma-phase-3-trusttsc-trial-of-oral-ganaxolone-fails-stock-plunges 2024-10-24T19:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/2864c9b19b3e32da/chemotherapy-combinations-and-the-phase-3-duo-e-trial-cancer-network 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/1129344bd69532b2/pembrolizumab-regimens-earn-european-approvals-in-gynecologic-cancers 2024-10-24T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/efde0951b0cf99d8/targeted-therapy-and-immunotherapy-improve-outcomes-in-rare-thyroid-cancer 2024-10-24T19:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/1234f3d16dac9fe1/connecting-ayas-to-quality-cancer-care-nci 2024-10-24T19:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/24651ee6845f6dcf/inmune-bio-inc-announces-publication-in-cell-reports-demonstrating-xprotm-promotes 2024-10-24T19:20:03+00:00 weekly 0.7 https://trial.medpath.com/news/2850ba408296e63e/new-analysis-links-novo-s-semaglutide-to-reduced-risk-of-alzheimer-s-disease-medwatch 2024-10-24T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/e406b271b0d474b8/new-first-in-class-drug-approved-for-advanced-stomach-cancer-webmd 2024-10-24T19:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/1ca3c4a0e9810a51/approval-of-bevacizumab-biosimilar-could-eliminate-access-to-low-cost-amd-therapy 2024-10-24T19:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/3feb1b50a13d2b7b/gilead-utilizes-a-counterintuitive-approach-to-improve-metabolic-stability-of-an-hiv-protease-inhibitor 2024-10-24T18:54:26+00:00 weekly 0.7 https://trial.medpath.com/news/b441567e0b0c6765/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:51:46+00:00 weekly 0.7 https://trial.medpath.com/news/30c1c3d44a3c9eef/unravel-biosciences-and-pecet-announce-collaboration-to-conduct-clinical-trials-of-rvl 2024-10-24T18:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/218f70e1e74af562/mrd-a-game-changer-in-multiple-myeloma-american-journal-of-managed-care 2024-10-24T18:37:02+00:00 weekly 0.7 https://trial.medpath.com/news/86199e2f98c5278c/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-biospace 2024-10-24T18:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/d8d5e05240f2f4e3/birchbiomed-clinical-program-reaches-final-stage-to-minimise-burn-scars 2024-10-24T18:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/df6e3078c8a9e6d8/2024-regulatory-approvals-across-nsclc-propel-the-therapeutic-landscape-forward 2024-10-24T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/f803a73cd81d9dbe/combining-targeted-therapy-and-immunotherapy-improves-overall-survival-in-patients-with 2024-10-24T17:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/4b8a4b6201ae86f1/step-up-your-practice-start-treating-fip-today-dvm360 2024-10-24T17:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/46413a565e6bad86/fda-finalizes-guidance-on-use-of-part-11-electronic-systems-records-and-signatures-in 2024-10-24T17:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/b8e3c1293283cd54/lack-of-support-for-dementia-carers-highlighted-as-clinical-trial-launched 2024-10-24T17:19:56+00:00 weekly 0.7 https://trial.medpath.com/news/5617603b8d895fda/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials 2024-10-24T17:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/6b9d4d9c62e46ea5/anaphylm-sublingual-film-achieves-rapid-resolution-of-allergen-related-symptoms 2024-10-24T17:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/f98e5f172d7483e2/alzheimer-s-drug-trials-raise-ethical-concerns-over-risk-disclosure-becker-s-hospital-review 2024-10-24T16:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/8c0b64fb4cd0b82b/women-beginning-chemotherapy-for-breast-cancer-self-report-improved-cognitive 2024-10-24T16:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/de0aeb05f399b29d/drugs-like-ozempic-and-wegovy-are-linked-to-a-lower-risk-of-alzheimer-s-disease-new-study-says 2024-10-24T16:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/beef70ac88eb6cc4/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/77f1f0c81b9a1227/oryzon-reports-financial-results-and-corporate-update-for-quarter-ended-september-30-2024 2024-10-24T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/480eba4798b096e2/popular-diabetes-and-weight-loss-drug-may-reduce-risk-of-alzheimer-s-disease 2024-10-24T16:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/96ece6df526afcdf/pembrolizumab-earns-eu-approval-in-2-new-indications-for-endometrial-and-cervical-cancer 2024-10-24T16:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/4302f71a49cbc691/fda-grants-priority-review-for-tlx101-cdx-pet-imaging-agent-in-glioma 2024-10-24T16:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/6a2bad9196db8374/fda-approved-alzheimer-s-drug-could-save-lives-by-inducing-a-state-of-suspended-animation 2024-10-24T16:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/da97448516e388d6/septerna-raises-288m-in-upsized-ipo-to-advance-novel-gpcr-targeting-drug-pipeline 2024-10-24T15:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/1e3412af5a7669a9/phase-3-rise-up-study-of-mitapivat-for-scd-completes-enrollment 2024-10-24T15:32:56+00:00 weekly 0.7 https://trial.medpath.com/news/35e1c2e6e4b893a8/intellia-therapeutics-stock-plunges-after-phase-2-results-from-ntla-2002-study 2024-10-24T15:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/dfac44605a109f74/alzamend-neuro-sets-trial-dosage-for-al001-lithium-therapy-alzheimer-s-news-today 2024-10-24T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/00a7f75048d404f9/phase-ii-study-of-irinotecan-trifluridine-tipiracil-tas-102-plus-bevacizumab-as-a-later-line 2024-10-24T15:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/157dee0ed54c179a/fda-approves-next-gen-pulsed-field-ablation-catheter-for-paroxysmal-atrial-fibrillation 2024-10-24T15:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/d2b06625bdfba353/okyo-pharma-doses-first-subject-in-ok-101-phase-ii-trial-for-ncp 2024-10-24T15:09:22+00:00 weekly 0.7 https://trial.medpath.com/news/1a80660d9c1542a8/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T15:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/169dc1ae7dbd8ee9/new-topical-treatments-expand-options-for-dermatological-conditions-expert-highlights-ruxolitinib-and-roflumilast-advances 2024-10-24T15:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/08d38f11f2d9cdc5/intellia-presents-positive-results-from-the-phase-2-study-of-ntla-2002-an-investigational-in 2024-10-24T14:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/0f150ba725ec881e/myelomatch-program-opens-enrollment-for-acute-myeloid-leukemia-and-mds-news-medical 2024-10-24T14:55:32+00:00 weekly 0.7 https://trial.medpath.com/news/ee972809e468c92b/reading-the-signs-of-dementia-nature 2024-10-24T14:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/be1b1184cc0b2eba/euro-roundup-britain-proposes-postmarket-surveillance-law-in-first-major-update-to 2024-10-24T14:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/59b52a22334f9729/alzheimer-s-disease-semaglutide-use-linked-to-lower-risk-medicalnewstoday 2024-10-24T14:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/845c12408fdee655/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-24T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/2ab5eb1774519062/could-pdurs-be-the-game-changer-to-unlock-digital-therapeutics-td-securities 2024-10-24T14:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/7427f6ab79df040f/novo-nordisk-s-ozempic-may-reduce-risk-of-alzheimer-s-disease-study-cnbc 2024-10-24T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/430370e92b0dd732/nih-launches-precision-medicine-trial-to-test-new-treatments-for-myeloid-cancers 2024-10-24T14:25:35+00:00 weekly 0.7 https://trial.medpath.com/news/ad9e3306411ca1c9/lilly-s-kisunla-does-not-demonstrate-good-value-for-uk-s-nhs 2024-10-24T14:23:22+00:00 weekly 0.7 https://trial.medpath.com/news/fce948930aae9fa8/the-evolving-role-of-adjuvant-immunotherapy-in-resected-renal-cell-carcinoma 2024-10-24T14:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/2e266fbb8e3434b4/alto-neuroscience-s-depression-drug-trial-fails-at-phase-2-biopharma-reporter-com 2024-10-24T14:15:28+00:00 weekly 0.7 https://trial.medpath.com/news/62a5700c2090ee6b/are-norovirus-vaccines-on-the-horizon-medpage-today 2024-10-24T14:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/7e16d90862759d3d/upcoming-discussion-on-recent-advances-in-head-and-neck-cancer-clinical-trials 2024-10-24T14:08:02+00:00 weekly 0.7 https://trial.medpath.com/news/07439d9b79c01096/a-new-lease-on-life-procedure-relieves-patients-tremors-in-both-hands-newsroom 2024-10-24T14:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/9971d9b0c0d4a786/new-alzheimer-s-drug-approved-in-uk-but-government-won-t-pay-for-it-euronews 2024-10-24T14:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/ae23b9d903e38258/ec-approves-darzalex-sc-with-vrd-for-newly-diagnosed-multiple-myeloma-patients 2024-10-24T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/c328d0b8b882db98/october-24-2024-apa-sm-trial-joins-the-nih-pragmatic-trials-collaboratory 2024-10-24T13:50:36+00:00 weekly 0.7 https://trial.medpath.com/news/de108ca4da2ab23a/icddr-b-s-breakthrough-research-leads-to-who-s-approval-of-single-dose-cecolin-vaccine-for 2024-10-24T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/fa4f61aad0a75f03/health-and-wellness-sector-sees-new-opportunities-in-weight-loss-drug-market 2024-10-24T13:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/5a8ee09ebb28bc25/genprex-announces-sponsored-research-agreement-with-the-university-of-michigan-stock-titan 2024-10-24T13:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/25c4100fee14a270/aulos-bioscience-presents-phase-2-dose-selection-data-for-novel-il-2-therapeutic 2024-10-24T13:25:58+00:00 weekly 0.7 https://trial.medpath.com/news/927f200e284b4ea1/health-check-approval-clock-ticks-as-fda-accepts-telix-s-brain-diagnostic-marketing-application 2024-10-24T13:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/e31cebad9e03ab9e/new-hope-for-rapid-acting-depression-treatment-national-institute-of-mental-health 2024-10-24T13:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/4ad7e1aee60180c1/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted 2024-10-24T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/deabee78998efb3f/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/2f6fcdf46c30a77c/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-stock-titan 2024-10-24T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/3853008cec3d1520/iasis-molecular-takes-next-steps-to-develop-two-products-spokane-journal-of-business 2024-10-24T13:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/baaa55b410495a45/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica 2024-10-24T13:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/92cff3caaa71eead/intellia-reports-promising-phase-2-results-for-hae-treatment-investing-com 2024-10-24T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/2d2960325d66a94a/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-morningstar 2024-10-24T13:01:21+00:00 weekly 0.7 https://trial.medpath.com/news/4f9e61b3b32d4576/fda-grants-rare-pediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for 2024-10-24T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/5e9e59095949dfb9/new-analysis-shows-primec-significantly-improves-key-mirnas-in-als-patients 2024-10-24T12:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/affa6d0589b36e09/marinus-pharmaceuticals-announces-topline-results-from-phase-3-trusttsc-trial-of-oral 2024-10-24T12:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/a51fe2c4f5330733/accent-therapeutics-announces-fda-clearance-of-ind-application-for-atx-559-a-first-in 2024-10-24T12:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/65eff9273133cbf0/lytix-biopharma-highlights-positive-data-on-ltx-315-in-collaboration-with-verrica-finansavisen 2024-10-24T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/63855445ab4e5010/angiodynamics-launches-long-term-study-of-nanoknife-for-prostate-cancer 2024-10-24T12:15:58+00:00 weekly 0.7 https://trial.medpath.com/news/06186137c2f68951/press-release-dupixent-late-breaking-positive-phase-3-data-globenewswire 2024-10-24T12:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/07498fc9517738f1/glp-1-prescriptions-for-type-1-diabetes-spike-despite-lack-of-fda-approval-study 2024-10-24T12:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/67d7cb27a8953292/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/4069038fefde267f/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-global-phase-3-lugano-clinical 2024-10-24T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/3a2eb2521d3f2568/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-24T12:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/155db636854633b2/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/1e70dd258ece4410/erasca-announces-strong-momentum-for-naporafenib-and-ras-targeting-franchise 2024-10-24T12:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/8d37fb4e9134ec86/medera-announces-completion-of-cohort-a-and-initiation-of-dosing-in-cohort-b-of-music 2024-10-24T12:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/ff7e8b29f4e7fe4d/johnson-johnson-showcases-neuropsychiatry-innovations-at-psych-congress 2024-10-24T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e5e6e7c8e109116e/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked-biospace 2024-10-24T11:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/a6a4f4e09cfb66c0/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2024 2024-10-24T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/f33df3949da8fc59/pcl-faces-allegations-of-clinical-trial-manipulation-for-covid-19-test-kit 2024-10-24T11:43:35+00:00 weekly 0.7 https://trial.medpath.com/news/281f650dd41b56ca/caris-life-sciences-and-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-24T11:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/479d1c10c3ea87be/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/5951ffaf1a64ffd4/medtronic-s-prevail-dcb-pivotal-trial-receives-fda-ide-approval-medical-device-network 2024-10-24T11:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/def66bf361bd1dca/calluna-completes-cal101-phase-i-clinical-study-for-fibrotic-conditions 2024-10-24T11:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/1260ee3a55a92224/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-24T11:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/567ec346ee7a6de3/ozempic-linked-to-lower-alzheimer-s-risk-in-people-with-type-2-diabetes-nbc-news 2024-10-24T11:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/b4eb8e83d5b15295/ozempic-wegovy-might-help-lower-alzheimer-s-risk-in-people-with-diabetes 2024-10-24T11:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/ce6037fc0e890ffe/nih-launches-precision-medicine-trial-for-myeloid-cancers-clinical-trials-arena 2024-10-24T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/7685a706195d8760/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-pr-newswire 2024-10-24T11:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/5ed7e33b63e341f6/mindbio-announces-clinical-trial-milestone-in-phase-2b-microdosing-trials-targeting 2024-10-24T11:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/f79fcfba076b2446/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib 2024-10-24T11:03:52+00:00 weekly 0.7 https://trial.medpath.com/news/b27ea015fb3259a6/cancer-research-uk-and-kisoji-biotechnology-collaborate-to-advance-the-first-naked 2024-10-24T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/aed00211c32de7a2/i-participated-in-the-first-fda-approved-stem-cell-trial-for-ms-it-changed-my-life-popsugar 2024-10-24T10:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/8f3d86ef078ea7d7/myelomatch-precision-medicine-trials-in-myelo-eurekalert 2024-10-24T10:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/cd149a1db5aadd95/medigene-ag-reports-financial-results-and-business-update-for-q3-2024-biospace 2024-10-24T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/abf47ece9be7722a/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T10:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/0acd84f468db79b6/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical 2024-10-24T10:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/ef755e9c93b65110/gold-sirna-supraclusters-enhance-the-anti-tumor-immune-response-of-stereotactic-ablative 2024-10-24T10:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/c55f05eb23f1c344/implant-might-prevent-opioid-overdose 2024-10-24T10:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/7ee4ea5fd4564987/bicycle-switches-on-to-radiopharma-in-new-cancer-breakthrough-business-weekly 2024-10-24T08:32:08+00:00 weekly 0.7 https://trial.medpath.com/news/f91f3ea32b3d096b/be-bio-raises-82m-to-advance-haemophilia-b-gene-therapy-to-phase-i-ii-trial 2024-10-24T07:59:20+00:00 weekly 0.7 https://trial.medpath.com/news/4087c5331794450a/expert-highlights-diagnostic-challenges-and-trial-access-barriers-in-myeloproliferative-neoplasms 2024-10-24T07:39:43+00:00 weekly 0.7 https://trial.medpath.com/news/00082b475e318cd7/eli-lilly-launches-obesity-drug-in-denmark-hits-shelves-next-week-medwatch 2024-10-24T07:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/dcc5e9f312e5cf82/pierre-fabre-announce-1st-patient-dosed-in-phase-i-ii-of-pfl-002-vert-002-a-targeted 2024-10-24T07:27:55+00:00 weekly 0.7 https://trial.medpath.com/news/0d5b28e785a47929/supply-chain-evolution-critical-for-pharmaceutical-industry-s-shift-to-advanced-therapies 2024-10-24T07:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/d50331ab3e153303/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-24T06:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/c1437d569eb37449/receives-u-s-fda-fast-track-designation-for-the-novel-anti-respiratory-syncytial-virus 2024-10-24T06:12:24+00:00 weekly 0.7 https://trial.medpath.com/news/533dfa56b30fad9d/j-ints-bio-presents-interim-findings-from-phase-1-2-clinical-trial-of-4th-generation-egfr 2024-10-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/d0976f60a303226c/tens-of-thousands-of-uk-dementia-patients-to-be-enrolled-in-clinical-trials-the-guardian 2024-10-24T05:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/a27e249f8c1b2e35/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-24T05:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/94b88ff4fac5a269/evolving-complexity-in-ovarian-cancer-treatment-demands-better-decision-support-systems 2024-10-24T05:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/e461b98ca50f5c44/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara-r-brain-cancer-imaging-agent 2024-10-24T03:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/8b08d8849377f669/federal-officials-should-investigate-conduct-of-alzheimer-s-disease-trials-public-citizen 2024-10-24T03:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/2fb2db12903f1667/supervised-machine-learning-emerges-as-preferred-ai-solution-for-clinical-trials-over-large-language-models 2024-10-24T02:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/a337fa0e3c8e3cf5/hybrid-software-approach-emerges-as-new-paradigm-in-drug-development 2024-10-24T01:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/ccaeaa631167a8ff/expert-recommendations-for-germany-s-integration-of-psychedelic-assisted-therapy 2024-10-24T01:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/705e2517324f54dc/teva-s-denosumab-biosimilar-candidate-is-accepted-for-review-by-fda-and-ema 2024-10-24T01:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/6e2d2f2b4ca31625/on-the-nyt-article-what-drugmakers-did-not-tell-volunteers-in-alzheimer-s-trials 2024-10-24T01:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/90317144a9e271dd/everest-medicines-eyes-mrna-tumor-vaccines-as-drug-valuations-rebound-bamboo-works 2024-10-24T01:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/536ef3dac9b85fe8/intensive-chemotherapy-versus-standard-chemotherapy-among-patients-with-high-risk-the-bmj 2024-10-24T01:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/b0a4bf15537d4ce1/hope-medicine-inc-announces-positive-results-from-a-global-phase-2-study-of-a-first-in 2024-10-24T00:55:20+00:00 weekly 0.7 https://trial.medpath.com/news/a248cf6f6d4194ec/common-drug-shows-promise-in-extending-lifespan-usc-dornsife 2024-10-24T00:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/49ccdfcc78e1928c/alpha-9-becomes-latest-radiopharma-to-secure-funds-with-175m-series-c 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f5ef81df26db89a/aktis-oncology-s-first-in-class-nectin-4-radiopharmaceutical-aky-1189-shows-promising-tumor-uptake-across-multiple-cancer-types 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/77a752c555cce979/australian-court-invalidates-bayer-s-rivaroxaban-follow-on-patents-in-landmark-obviousness-ruling 2024-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3815a8d557177e53/upadacitinib-in-adolescents-with-moderate-to-severe-atopic-dermatitis-jama-network 2024-10-23T23:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/2c370634bd97a5d0/woodcock-rct-standards-not-fit-for-rare-disease-treatment-approval 2024-10-23T22:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/9252e92a08810d88/fda-accepts-new-drug-application-and-grants-priority-review-globenewswire 2024-10-23T22:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/8f9c9ad1960cc7e6/dr-ducreux-on-the-potential-use-of-liver-transplantation-plus-chemo-for-crc-liver-metastases 2024-10-23T20:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/a49528ab4e71b19b/european-medicines-agency-the-unilateral-authorization-of-sputnik-v-is-like-a-russian-roulette 2024-10-23T20:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/e37c11e25fc50f9a/are-you-a-healthy-african-american-between-the-ages-of-18-and-60-the-reporter-uab 2024-10-23T19:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/b9604a8e4e9504e9/fda-announces-device-trial-participation-snapshots-akin-gump 2024-10-23T19:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/2ba3f1a654c721e9/luna-diabetes-launches-trial-for-world-s-smallest-insulin-patch-pump 2024-10-23T18:25:50+00:00 weekly 0.7 https://trial.medpath.com/news/1816e9eadc733243/fast-acting-novel-depression-tx-lumryz-label-expanded-glp-1s-for-addiction 2024-10-23T18:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/0b30ab704e8f0579/utility-of-a-systolic-blood-pressure-polygenic-risk-score-with-chlorthalidone-response 2024-10-23T18:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/d8b2147b3bb083c6/gilead-in-talks-with-sahpra-to-register-twice-yearly-anti-hiv-jab-juta-medicalbrief 2024-10-23T18:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/4d5627bdc3bec1ee/can-takeda-help-treat-narcolepsy-the-medicine-maker 2024-10-23T18:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/e66eea2c83e81ccf/sangamo-to-seek-accelerated-approval-for-fabry-gene-therapy 2024-10-23T17:55:33+00:00 weekly 0.7 https://trial.medpath.com/news/ef177a1c28e681dd/effect-of-heart-rate-control-with-ivabradine-on-hemodynamic-in-patients-with-sepsis-trials 2024-10-23T17:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/7c4b69ef0986b51e/redhill-duke-collaborate-on-phosgene-inhalation-treatment-contract-pharma 2024-10-23T17:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/a1640caad3091550/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-10-23T16:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/2e94e1fe686acac7/cadonilimab-plus-chemo-an-option-for-cervical-cancer 2024-10-23T16:33:44+00:00 weekly 0.7 https://trial.medpath.com/news/7f28a590a56a1532/hibercell-receives-fda-fast-track-designation-for-hc-7366-for-the-treatment-of-relapsed 2024-10-23T16:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/729cfa7ce448c53e/llnl-unveils-breakthrough-fentanyl-overdose-treatment-mirage-news 2024-10-23T15:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/912a0eb62830abda/x-therma-announces-world-s-first-subzero-transatlantic-organ-transports 2024-10-23T15:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/f4e0d92eb13f9ad5/lixte-biotechnology-granted-extension-to-meet-nasdaq-listing-rules-investing-com-uk 2024-10-23T15:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/be0f757b27c6b4f3/fda-approves-ide-for-medtronic-prevail-drug-coated-balloon 2024-10-23T15:42:43+00:00 weekly 0.7 https://trial.medpath.com/news/60310745ae4c9ac2/a-new-therapy-to-prevent-or-delay-type-1-diabetes-now-available-at-unc-children-s-hospital 2024-10-23T15:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/f44fdc2593bf5bbd/i-spy2-2-dato-dxd-plus-durvalumab-yields-high-pathologic-response-rate-in-breast 2024-10-23T15:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/a986cd3593e75359/recursion-announces-first-patient-dosed-in-phase-2-clinical-study-of-rec-3964-a-potential 2024-10-23T15:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/7c6c9eea1390fd20/first-patient-dosed-with-in-vivo-gene-therapy-for-car-t-inside-precision-medicine 2024-10-23T15:13:52+00:00 weekly 0.7 https://trial.medpath.com/news/c8e000b256692ec4/modivcare-and-michigan-center-for-rural-health-partner-to-extend-care-access-by-quantisnow 2024-10-23T15:13:44+00:00 weekly 0.7 https://trial.medpath.com/news/8a9185408749ce78/fda-issues-crl-for-ketamine-to-treat-pain-mental-health-and-more-hcplive 2024-10-23T15:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/acb22f8ccc5dcd30/video-phase-3-geographic-atrophy-program-focuses-on-visual-acuity-healio 2024-10-23T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/news/7a968cdb7dec17f2/clinical-usefulness-of-digital-twin-guided-virtual-amiodarone-test-in-patients-with-atrial-nature 2024-10-23T14:49:12+00:00 weekly 0.7 https://trial.medpath.com/news/1d5b82078beabbf9/disappointing-phase-2b-results-for-alto-100-for-mdd-precision-medicine 2024-10-23T14:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/6ac933b430d4b921/atorvastatin-and-telmisartan-do-not-reduce-nasopharyngeal-carriage-of-sars-cov-2-in-mild 2024-10-23T14:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/a3f4d510b2b88ab5/kidney-transplant-noninferior-from-donors-with-versus-without-hiv-in-hiv-positive-recipients 2024-10-23T14:24:43+00:00 weekly 0.7 https://trial.medpath.com/news/345b8ab2a70404ed/prescription-digital-therapeutic-for-insomnia-improves-sleep-and-mental-health-neurology-advisor 2024-10-23T14:24:35+00:00 weekly 0.7 https://trial.medpath.com/news/ad0bc035dba72e7e/young-patient-s-recovery-from-debilitating-injury-inspires-return-to-miami-as-summer 2024-10-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/c62524be36a7d9b4/clinical-trial-media-sees-up-to-62-of-alzheimer-s-study-randomizations-from-diverse-populations 2024-10-23T13:55:58+00:00 weekly 0.7 https://trial.medpath.com/news/f987dc175973cb31/new-analysis-of-phase-3-data-demonstrating-renal-protective-benefits-of-sotagliflozin-to-be 2024-10-23T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/d1104484034928b0/wobble-genomics-unveils-breakthrough-early-detection-tech-for-breast-cancer-mercia 2024-10-23T13:21:42+00:00 weekly 0.7 https://trial.medpath.com/news/f69687f2be5e164f/a-slow-start-for-self-amplifying-mrna-vaccines-pharmaceutical-technology 2024-10-23T13:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/76912d34bf573860/a-phase-1a-1b-study-of-fostroxacitabine-bralpamide-fostrox-monothera-jhc-dove-medical-press 2024-10-23T12:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/b085821c668cedc7/join-biovie-s-exclusive-live-investor-webinar-and-q-a-session-on-november-7th-2024 2024-10-23T12:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/fab549ffaa0f9469/calluna-pharma-completes-successful-phase-1-trial-of-new-fibrotic-disease-drug 2024-10-23T12:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/afde33650532c5dd/aao-2024-phase-ii-study-on-the-safety-of-intravitreal-nt-501-encapsulated-cell-therapy 2024-10-23T12:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/c45eb68a38e0d621/agios-completes-enrollment-of-phase-3-rise-up-study-of-mitapivat-in-sickle-cell-disease 2024-10-23T11:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/76e80a2a19900d21/gilead-sciences-covid-19-treatment-to-receive-reimbursement-pharma-article-kbr 2024-10-23T11:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/2e2e2edfa9d320b6/repare-therapeutics-announces-updated-positive-safety-and-tolerability-results-from-the 2024-10-23T11:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/1a4946ec3cd5ef9c/elan-class-action-news-elanco-animal-health-incorporated-globenewswire 2024-10-23T11:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/efe52eb81381031f/oric-114-demonstrates-potential-in-preclinical-cancer-study 2024-10-23T11:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/787b4c7c49244803/nma-reveals-vabysmo-s-superior-cst-improvement-over-eylea-hd 2024-10-23T10:45:17+00:00 weekly 0.7 https://trial.medpath.com/news/d008d454a8ce30f2/ps3m-for-world-first-trial-to-revolutionise-brain-cancer-treatment 2024-10-23T10:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/bbfc08c1fe3a438b/lilly-s-alzheimer-s-drug-gets-uk-nod-but-won-t-be-nhs-funded-pharmaphorum 2024-10-23T10:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/96fc8544ab8919b2/covid-in-pregnancy-won-t-lead-to-neurodevelopmental-issues-in-kids 2024-10-23T10:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/a57293120011c904/aerobic-exercise-may-ease-brain-fog-of-breast-cancer-chemo 2024-10-23T10:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/7fa23eb065425068/mri-might-spare-rectal-cancer-patients-surgery-and-colostomy 2024-10-23T10:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/3de0d7be2215bf95/fully-automated-ai-based-system-developed-for-ivf-embryo-quality-assessment 2024-10-23T09:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/bc972420c3dd13c8/aligos-therapeutics-announces-u-s-fda-clearance-of-ind-application-for-alg-000184 2024-10-23T09:20:22+00:00 weekly 0.7 https://trial.medpath.com/news/66185605a9e40382/positive-chmp-opinion-for-siiltibcy-tuberculosis-skin-test-webdisclosure 2024-10-23T08:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/4b434f296cc685f0/jiangsu-recbio-launches-phase-iii-trial-for-shingles-vaccine-markets-insider 2024-10-23T08:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/101d49c6f64a9c46/methadone-outperforms-other-opioid-treatments-in-keeping-patients-in-care 2024-10-23T08:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/66dab3b0b3fb90ed/panavance-details-ind-prep-ahead-of-fda-submission-for-ovarian-cancer-trial 2024-10-23T07:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/221767a0e3607f5d/ondine-biomedical-inc-announces-king-s-college-hospital-to-run-steriwave-pilot-webdisclosure 2024-10-23T06:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/4ba3dc9aba8955b2/eisai-expects-eu-decision-on-bioarctic-s-lecanemab-in-q2-marketscreener 2024-10-23T05:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/23f601da5d3cfee7/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-globenewswire 2024-10-23T05:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/b8e5ef7389501509/experts-call-for-mandatory-clinical-trial-training-in-hematology-oncology-fellowship-programs 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3be016ba03dc364/patient-centric-revolution-how-patient-insights-are-transforming-modern-drug-development 2024-10-23T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b37e48caf5aca788/grx-biosims-panelists-discuss-regulatory-shifts-in-biosimilar-interchangeability 2024-10-23T02:09:43+00:00 weekly 0.7 https://trial.medpath.com/news/c44a2aba1678bc30/it-was-just-so-quick-new-drug-to-help-patients-like-mark-before-it-s-too-late-daily-liberal 2024-10-23T02:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/4853eb84976abe24/long-acting-hiv-therapies-show-promise-amid-policy-challenges-idweek-2024-highlights 2024-10-23T01:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/a7bd5ef21d51b32c/the-one-mutation-that-could-change-cancer-therapy-forever-synbiobeta 2024-10-23T01:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/f9b937f149709b3a/alzheimer-s-wonder-drug-will-be-blocked-by-nhs-from-today-due-to-cost-daily-mail 2024-10-23T01:12:11+00:00 weekly 0.7 https://trial.medpath.com/news/30280267d74a6a4a/mind-diet-and-cognitive-decline-gene-therapy-for-parkinson-s-curbing-ms-fatigue 2024-10-23T01:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/f7e2005c68023df1/ocuphire-pharma-acquires-opus-genetics-modern-retina 2024-10-22T22:54:38+00:00 weekly 0.7 https://trial.medpath.com/news/52b4d5bb498c8bc3/algorae-pharmaceuticals-launches-ai-platform-and-advances-drug-trials-tipranks-com 2024-10-22T22:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/606c9db997f3f5dc/siemens-healthineers-wins-fda-nod-for-heart-attack-predicting-test-massdevice 2024-10-22T22:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/1bf092c0d269a4b8/fda-clears-gentuity-imaging-system-for-coronary-interventions-massdevice 2024-10-22T22:43:30+00:00 weekly 0.7 https://trial.medpath.com/news/be328a330790be7b/scientists-glue-two-proteins-together-driving-cancer-cells-to-self-destruct-news-center 2024-10-22T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/e7f015ce388e4d8a/carmen-lc03-tusamitamab-ravtansine-vs-docetaxel-in-previously-treated-advanced 2024-10-22T21:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/e2ca9d78f60e253d/genelux-corporation-announces-first-patient-dosed-in-phase-2-trial-evaluating-systemic 2024-10-22T21:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/6a421581feabb5fa/on-off-switch-for-car-t-cell-therapy-shows-early-promise-inside-precision-medicine 2024-10-22T20:57:23+00:00 weekly 0.7 https://trial.medpath.com/news/73d34ba80c07c53d/dbv-announces-positive-regulatory-updates-for-the-viaskin-r-globenewswire 2024-10-22T20:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/9d64d4f025c454bf/cothera-bioscience-announces-fda-fast-track-designation-for-clinical-program-pc-002 2024-10-22T20:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/5c324a84f8ce16a7/u-s-fda-approves-pfizer-s-rsv-vaccine-abrysvo-r-for-adults-aged-18-to-59-at-increased 2024-10-22T20:54:38+00:00 weekly 0.7 https://trial.medpath.com/news/6d2b87171aee44c6/recon-fda-rejects-camurus-rare-hormone-disorder-drug-amgen-to-launch-eylea-raps 2024-10-22T20:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/02e452bbfd85b89d/fda-approval-for-biktarvy-issued-to-gilead-sciences-inc-quantisnow 2024-10-22T20:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/95cdd4ec8300c684/gyre-therapeutics-announces-last-patient-completed-pivotal-phase-3-trial-evaluating 2024-10-22T20:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/9be50c1a8738b24f/neoadjuvant-chemotherapy-becomes-leading-initial-treatment-for-advanced-epithelial 2024-10-22T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/10811f4f36d36abe/oncternal-therapeutics-announces-updated-safety-and-efficacy-data-for-phase-1-2-study-of 2024-10-22T19:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/e3fac2234091fd36/first-patient-to-receive-breakthrough-sickle-cell-gene-therapy-leaves-hospital 2024-10-22T18:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/e73eb0c7f792ca1e/gilead-to-present-latest-research-across-key-liver-disease-indication-at-the-american 2024-10-22T18:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/9c80cc629d5da346/nido-biosciences-announces-orphan-drug-designation-for-lead-clinical-candidate-to-treat 2024-10-22T18:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/701ddcff8258dc19/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to 2024-10-22T18:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/4a5b3a9a75b26196/me-therapeutics-holdings-inc-provides-research-and-development-update-and-corporate-update 2024-10-22T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/92bf1780c90cca89/a-common-genetic-variant-may-guide-precision-therapy-for-sickle-cell-disease 2024-10-22T17:45:09+00:00 weekly 0.7 https://trial.medpath.com/news/cbedb587abfb09fa/gene-therapy-clinical-trial-pipeline-gains-momentum-180-companies-lead-the-charge 2024-10-22T17:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/f17fe42f37b687ef/evaluating-efficacy-and-safety-of-ocrelizumab-biosimilar-xacrel-compared-to-the-originator 2024-10-22T16:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/abdbc108f96dbfae/outcomes-with-adjuvant-ici-treatment-in-resected-stage-iii-iv-melanoma-the-asco-post 2024-10-22T16:53:29+00:00 weekly 0.7 https://trial.medpath.com/news/f70c1f686857c192/cosmetic-outcomes-with-two-schedules-of-partial-breast-irradiation-in-early-breast-cancer 2024-10-22T16:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/4243842f458c7a4d/peytant-wins-fda-de-novo-nod-for-covered-stent-system-massdevice 2024-10-22T16:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/3c2e6c1462e6503f/annovis-to-highlight-buntanetap-s-alzheimer-s-research-progress-with-presentations-at-ctad-2024 2024-10-22T16:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/f254a8d488a2fe52/study-pharmacokinetics-safety-comparable-between-ct-p13-autoinjector-and-pre-filled-syringe 2024-10-22T16:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/d03909f48720bcc9/celmatix-achieves-milestone-in-development-of-oral-fertility-drug-femtech-insider 2024-10-22T16:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/97875ae5c34c589d/omega-3s-for-heart-health-exploring-potential-benefits-and-risks-nhlbi 2024-10-22T16:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/c7d29ad8345b5675/vivos-therapeutics-secures-fda-clearance-for-pediatric-osa-device-secures-new-ama-cpt-codes 2024-10-22T16:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/ee09845db0851a2c/zoledronic-acid-treatment-reduces-fracture-rate-in-pediatric-patients 2024-10-22T15:58:14+00:00 weekly 0.7 https://trial.medpath.com/news/6997586da63b98ad/topical-on101-is-superior-to-conventional-dressing-for-some-diabetic-foot-ulcers 2024-10-22T15:58:13+00:00 weekly 0.7 https://trial.medpath.com/news/303d1428587f1e59/lecanemab-tops-other-antibodies-at-binding-soluble-ab-aggregates-alzforum 2024-10-22T15:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/0324ab71c94fa96e/have-you-been-diagnosed-with-lupus-the-reporter-uab 2024-10-22T15:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/e6862c5591a07136/heal-initiative-jcoin-phase-ii-community-engaged-research-resource-center-josh-gottheimer 2024-10-22T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/69fccc66b26727bc/roche-trims-another-alzheimer-s-prospect-ending-ucb-collabortion-biospace 2024-10-22T15:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/daca06b6a4f5b266/telo-genomics-corp-presents-new-performance-data-for-its-smoldering-myeloma-prognostic-test 2024-10-22T15:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/c343a5d672d3644c/hansoh-pharmaceutical-group-company-limited-announces-phase-iii-registrational-trial 2024-10-22T15:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/905daaaa04fd9a1a/vcu-liver-specialist-partners-with-patient-group-to-study-rare-diseases-impact 2024-10-22T15:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/e5eb9974e48b3614/complement-activation-and-lung-injury-in-japanese-patients-with-covid-19-nature 2024-10-22T15:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/eb2c92b79e7974ea/prausnitz-elected-to-national-academy-of-medicine-georgia-tech-college-of-engineering 2024-10-22T14:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/5ce111bd2397ff88/breakthrough-drug-for-motor-neurone-disease-shows-promise-in-new-study-durham-university 2024-10-22T14:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/164bc424a4dd804d/post-transplant-lymphoproliferative-disorder-drug-pipeline-globenewswire 2024-10-22T13:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/9c975f16d24d5397/cogt-stock-hits-52-week-high-at-12-2-amid-market-optimism 2024-10-22T13:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/ec8c3ae6773939d2/artera-receives-california-lab-license-expanding-access-to-its-arteraai-prostate-test 2024-10-22T13:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/ea18bc0baf752753/fiocruz-will-lead-the-first-clinical-trial-of-a-leprosy-vaccine-in-brazil 2024-10-22T13:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/3edb3826eac7b671/sangamo-therapeutics-announces-alignment-with-fda-on-accelerated-approval-pathway 2024-10-22T13:02:57+00:00 weekly 0.7 https://trial.medpath.com/news/8a1ea04f58d3cb02/the-effect-of-coaching-on-health-information-literacy-in-patients-with-chronic-kidney-disease 2024-10-22T12:48:56+00:00 weekly 0.7 https://trial.medpath.com/news/d1042a04fba81747/breakthrough-in-neurological-treatment-polish-researchers-develop-promising-new-molecule 2024-10-22T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/80de0deeec8e8e1a/pds-biotechnology-presents-rationale-design-for-study-evaluating-pds01adc-tipranks 2024-10-22T12:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/d05018b378a3ce9b/quoin-pharmaceuticals-announces-further-international-globenewswire 2024-10-22T12:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/51bb3f598197925a/autobahn-therapeutics-announces-fda-clearance-of-ind-application-for-abx-002-as-an 2024-10-22T12:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/dbf3829e1548621c/lexicon-announces-completion-of-screening-in-phase-2b-progress-study-of-lx9211-stock-titan 2024-10-22T12:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/76b0021228cd0642/awakn-announces-opening-of-four-additional-awkn-001-phase-3-trial-sites 2024-10-22T11:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/deee511db7ef1c1f/gradient-denervation-technologies-appoints-stanton-rowe-to-board-of-directors-morningstar 2024-10-22T11:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/ab545ad0cd246f9e/first-participants-enrolled-in-first-in-human-phase-i-clinical-trial-with-nociceptin-nop-receptor-agonist 2024-10-22T11:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/37d0c47b3b3ac8da/us-fda-declines-to-approve-camurus-rare-hormone-disorder-drug-the-mighty-790-kfgo 2024-10-22T11:24:11+00:00 weekly 0.7 https://trial.medpath.com/news/eac61a3d219b1f39/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi 2024-10-22T11:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/13ef98dbf94c6f51/data-and-safety-monitoring-board-approves-initiation-of-phase-2-of-ocu410st-globenewswire 2024-10-22T11:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/84319937691c9265/athira-pharma-to-present-results-from-phase-2-3-lift-ad-clinical-trial-of-fosgonimeton-at 2024-10-22T11:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/0c9be13f3961425a/ucb-announces-bepranemab-phase-2a-study-results-accepted-for-late-breaking 2024-10-22T11:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/78b41394ab47e80e/immunic-announces-positive-outcome-of-interim-analysis-of-phase-3-ensure-program-of 2024-10-22T10:54:55+00:00 weekly 0.7 https://trial.medpath.com/news/870246d05942d32c/otsuka-eyes-early-filing-of-igan-drug-after-phase-3-readout-pharmaphorum 2024-10-22T10:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/99f2b44cf2ba74e1/minghui-pharmaceutical-inc-announces-positive-topline-results-from-phase-ib-ii-clinical 2024-10-22T10:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/5c0a56d747e1c1ae/could-caffeine-in-pregnancy-help-prevent-cerebral-palsy-in-kids 2024-10-22T10:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/30109ecf9f871457/light-therapy-might-help-ease-dry-form-of-macular-degeneration 2024-10-22T10:01:08+00:00 weekly 0.7 https://trial.medpath.com/news/ecdddb79fde8919b/help-therapeutics-secures-fda-approval-for-phase-i-study-of-hicm-188-in-heart-failure-treatment 2024-10-22T09:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/194b998960a75698/our-viewpoint-new-aids-drug-the-witness 2024-10-22T09:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/30090152fddfaa08/ariceum-therapeutics-presents-promising-data-on-225ac-satoreotide-at-eanm-2024 2024-10-22T08:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/39a302b40dd92618/expert-outlines-strategies-to-improve-access-and-diversity-in-hr-her2-breast-cancer-clinical-trials 2024-10-22T08:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/e46e9847da6d1eca/assessing-the-effectiveness-and-safety-of-virtual-reality-in-treating-functional-dyspepsia 2024-10-22T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/6109db599a8116b7/pyc-provides-an-interim-update-on-progress-in-rp11-repeat-dose-clinical-trials-biotech 2024-10-22T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/0cec08f731afc543/faron-s-capital-markets-day-2024-cision-news 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/58bb98968eca4cc9/akiram-therapeutics-drug-candidate-akir001-cleared-to-start-phase-1-clinical-trial 2024-10-22T06:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/d0981fbbf8c078a7/eli-lilly-sues-mangorx-over-alleged-tirzepatide-weight-loss-drug-copycats 2024-10-22T05:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/67925f68aa0165a8/clinical-trial-disruption-patterns-reveal-regional-variations-and-rising-role-of-decentralized-studies 2024-10-22T05:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/ab57f4e928d45a45/u-s-fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-disease 2024-10-22T05:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/dd52924cf6ea60a8/clinical-trial-experts-outline-strategies-to-combat-patient-retention-and-manufacturing-challenges 2024-10-22T04:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/6db3317888b13b99/alvotech-and-teva-announce-u-s-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications-approved-for-reference-product-stelara-ustekinumab 2024-10-22T04:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/a70301f981e156c9/reflexology-shows-promise-in-reducing-stress-and-pain-for-breast-cancer-patients-during-radiotherapy 2024-10-22T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/80d767fb11762872/uptake-of-health-economic-evaluations-alongside-clinical-trials-in-australia-an-observational-study 2024-10-22T01:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/7c608e9a0610e2f0/revolution-medicines-announces-first-patient-dosed-in-phase-3-study-evaluating-rmc 2024-10-22T01:55:51+00:00 weekly 0.7 https://trial.medpath.com/news/8690d670461d3a48/europe-s-clinical-trial-leadership-declines-as-china-doubles-market-share-over-past-decade 2024-10-22T01:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/c29d38786daaf7d8/darling-ingredients-announces-publication-of-peer-reviewed-collagen-peptides-study-and-its-impact-on-post-meal-blood-glucose-spikes 2024-10-22T01:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/025f443d37fa2bcd/france-imposes-strict-conditions-on-sanofi-s-eur16-billion-opella-healthcare-sale-to-cd-r 2024-10-22T00:40:07+00:00 weekly 0.7 https://trial.medpath.com/news/713630d87e1f3bc9/indaptus-therapeutics-announces-clinical-supply 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b195bcf327bf95d2/fda-recalls-7107-bottles-of-generic-duloxetine-over-carcinogenic-chemical-contamination 2024-10-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b5ec84c784d76ce4/research-finds-breakthrough-in-autoimmune-therapy-mirage-news 2024-10-21T23:39:18+00:00 weekly 0.7 https://trial.medpath.com/news/7d1d52a987d738d8/recce-from-no-more-tears-to-no-more-superbug-fears-forbes-australia 2024-10-21T21:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/b7a461c35bdc83be/phase-1-trials-provide-oncology-fellows-with-valuable-clinical-research-experience-onclive 2024-10-21T21:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/969a9b6319637640/boston-scientific-scores-2-key-fda-approvals-for-pfa-mapping-technology 2024-10-21T20:58:37+00:00 weekly 0.7 https://trial.medpath.com/news/e155d66a86a2c4d9/recon-sanofi-in-talks-to-sell-its-consumer-business-opella-novo-s-rybelsus-cut-heart-risks-raps 2024-10-21T20:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/a42d83f9c134d6e9/irhythm-technologies-receives-fda-510-k-clearance-for-design-updates-previously 2024-10-21T20:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/6a456e3d621444d8/cerevance-announces-publication-of-positive-phase-2-results-of-solengepras-for-the-biospace 2024-10-21T18:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/9a4754e6c6c59343/abionyx-pharma-received-positive-feedback-from-the-ema-for-cer-001-in-lcat-deficiency 2024-10-21T18:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/1022b7fa75926d82/amneal-receives-u-s-fda-approval-of-new-drug-application-for-pyridostigmine-bromide 2024-10-21T17:52:27+00:00 weekly 0.7 https://trial.medpath.com/news/eb9d13c8cf87b4fc/nonopioid-suzetrigine-demonstrates-positive-phase-3-results-for-acute-pain-asa-2024 2024-10-21T17:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/2669adfa112c0b0e/rogaratinib-atezolizumab-in-cisplatin-ineligible-fgfr-mrna-overexpressing-urothelial-cancer 2024-10-21T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/851ac85acba3e0b8/funda-meric-bernstam-m-d-elected-to-national-academy-of-medicine 2024-10-21T16:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/7b38518f18e8d118/valneva-two-year-antibody-persistence-and-safety-of-a-single-dose-live-attenuated 2024-10-21T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/39553a12a1e23e68/special-session-bill-will-allow-marshall-clinic-to-study-medication-assisted-treatment 2024-10-21T16:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/31199c05b12a6fee/communities-that-heal-intervention-and-mortality-including-polysubstance-overdose-deaths 2024-10-21T15:55:41+00:00 weekly 0.7 https://trial.medpath.com/news/93af77e888d3be0a/endospan-hits-enrolment-milestone-in-aortic-arch-stent-trial-medical-device-network 2024-10-21T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/d2b2212a1b133817/bringing-hd-treatments-to-market-the-role-of-regulatory-oversight-hdbuzz 2024-10-21T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/d4c3132c84da0cd6/three-vs-6-cycles-of-chemotherapy-for-high-risk-retinoblastoma-a-randomized-clinical-trial 2024-10-21T15:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/6e657e272d2de725/expert-reaction-to-study-looking-at-a-home-based-transcranial-direct-current-stimulation 2024-10-21T15:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/52a2a7304423f093/health-canada-approves-arcutis-zoryve-foam-for-seborrheic-dermatitis 2024-10-21T14:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/3f796f0a7f608242/a-propensity-score-matching-study-nature 2024-10-21T14:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/9346cd77f208e7cd/why-lenz-therapeutics-stock-hit-a-new-52-week-high-today-benzinga 2024-10-21T14:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/f7170c83153fc1f3/seaport-therapeutics-winds-up-usd-225mn-series-b-financing-round 2024-10-21T14:37:28+00:00 weekly 0.7 https://trial.medpath.com/news/8e7f030d4cf3c4a1/through-a-13m-nci-grant-a-team-of-massey-scientists-could-change-the-way-liver-cancer-is-treated 2024-10-21T14:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/d975709031dccce0/3-2-million-per-dose-elevidys-fails-to-meet-primary-endpoint-in-phase-3-trial 2024-10-21T14:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/5b1739ca3bfd933b/percutaneous-arterial-bypass-for-long-fem-pop-lesions-uses-expand-as-experience-mounts 2024-10-21T14:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/9c181bbb2fb7ce24/find-therapeutics-dosing-subjects-in-study-of-ftx-101-for-chronic-optic-neuropathy 2024-10-21T14:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/007eca05e9a47fce/nvo-breakthrough-rybelsus-reduces-heart-attack-and-stroke-risk-in-study-gurufocus 2024-10-21T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/1271d0d6c55f0e59/reduced-inflammation-in-axspa-does-not-always-translate-into-clinical-improvement 2024-10-21T13:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/6609318d70c4ac12/ema-to-work-more-closely-with-the-european-commission-on-assessments-medwatch 2024-10-21T13:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/e097ae368a91a689/protara-therapeutics-announces-fast-track-designation-for-intravenous-choline-chloride 2024-10-21T12:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/d7760b6b2efdc02b/october-21-2024-best-icu-and-chat-4-heart-health-have-updated-study-snapshots 2024-10-21T12:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/199985581e82c567/inovio-announces-new-data-at-scientific-conferences-for-lead-candidate-ino-3107-as-a 2024-10-21T12:39:50+00:00 weekly 0.7 https://trial.medpath.com/news/4e493a781c1a6d22/veru-to-present-at-obesityweek-meta-analysis-of-4-previous-randomized-clinical-trials 2024-10-21T12:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/1fde61d55253b8e2/mira-pharmaceuticals-announces-ketamir-2-outperforms-current-fda-approved-newswire 2024-10-21T12:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/4b0a446826b2080d/lantern-pharma-to-host-participate-in-two-public-webinars-during-october-stock-titan 2024-10-21T12:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/738f152f3771edaf/nevada-king-intercepts-9-1m-of-4-32-g-t-au-extending-mineralization-420 2024-10-21T12:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/e3af9c499bfa3be9/windtree-to-present-at-the-thinkequity-conference-on-october-30th-globenewswire 2024-10-21T12:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/e7ee05b81bb456b7/biomed-industries-presents-phase-i-results-of-its-oral-quadruple-receptor-agonist-na-931 2024-10-21T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/e3fb1e31088a79fe/phase-3-trials-of-pd-1-pd-l1-inhibitors-in-nmibc-urology-times 2024-10-21T12:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/402d90ffa0b67663/lenz-therapeutics-announces-fda-acceptance-of-new-drug-globenewswire 2024-10-21T12:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/3d70c859fa1eede4/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4-s-nsclc-therapy-yahoo 2024-10-21T11:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/e2ae200fc261d251/acurx-reports-positive-phase-2-results-for-cdi-treatment-ibezapolstat-by-investing-com 2024-10-21T11:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/eb04b57868f7bf4f/regenxbio-presents-positive-data-from-the-phase-ii-study-of-subretinal-abbv-rgx-314-in 2024-10-21T11:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/dfad3fc09935404e/fibrobiologics-charles-river-agree-on-therapies-manufacture-pharmaceutical-technology 2024-10-21T11:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/5ef3c718d3ff6700/nuclidium-s-copper-based-radiotracer-shows-enhanced-imaging-performance-in-first-prostate-cancer-patient 2024-10-21T10:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/e72e986970786b88/news-engineered-polymers-show-promise-for-systemic-mrna-delivery-to-lungs 2024-10-21T10:58:17+00:00 weekly 0.7 https://trial.medpath.com/news/da2e349831870f02/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw171-biospace 2024-10-21T10:41:02+00:00 weekly 0.7 https://trial.medpath.com/news/64e53efeb28298b3/clinical-frailty-scale-score-is-a-predictor-of-short-mid-and-long-term-mortality-in-critically-ill 2024-10-21T10:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/a34d758575f7f8ed/beigene-receives-positive-chmp-opinions-for-tevimbra-r-as-a-first-line-treatment-via-ritzau 2024-10-21T10:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/9fcc7ffbc4789ec2/blood-test-might-spot-women-in-labor-at-risk-for-preeclampsia 2024-10-21T10:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/c08cb80f84d5b9b8/tenaya-therapeutics-cleared-to-move-onto-higher-dose-cohort-in-trial-of-hypertrophic 2024-10-21T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/233062e1d888e33c/after-shingles-damaged-her-vision-this-former-eye-surgeon-looked-for-a-way-to-keep-it-from 2024-10-21T08:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/2fb83bf0e817457d/senolytics-to-slow-progression-of-sepsis-stop-sepsis-in-elderly-patients-study-protocol-trials 2024-10-21T08:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/0880858529435632/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr 2024-10-21T08:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/0f3291b4848c8fc7/new-podcast-kidney-compass-launches-to-navigate-complex-landscape-of-nephrology-clinical-trials 2024-10-21T08:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/2bb2cace1a071cb6/dr-john-conibear-on-the-evolution-of-durvalumab-in-nsclc-care 2024-10-21T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/2b562fc571cfd8c9/chmp-recommends-ten-new-medicines-medwatch 2024-10-21T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/b4f6183f535d23f0/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-r-catumaxomab-in-eqs-news 2024-10-21T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/ac33a41ad2b675ef/ananda-developments-epilepsy-trials-research-tree 2024-10-21T06:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/14d85ef8150f93b4/asds-2024-new-phase-iii-ready-4-data-demonstrate-long-term-safety-and-efficacy-of 2024-10-21T06:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/31a233199ec928f3/advanced-technologies-transform-quality-assurance-in-emerging-cell-and-gene-therapies 2024-10-21T05:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/b9278d147bf7206f/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2024-10-21T05:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/0a530af452552885/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-21T05:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/a851325fac67995a/washington-university-s-clinical-trial-development-program-shows-success-in-training-future-investigators 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bad6e6eb1161a0e0/understanding-alternative-pathways-to-access-non-fda-approved-medications-a-comprehensive-review 2024-10-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/17cee5740c2bdd2e/blue-lake-biotechnology-and-cyanvac-announce-presentation-on-intranasal-vaccine 2024-10-21T04:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/84537af77e31d1f6/hyperbaric-oxygen-therapy-in-the-treatment-of-late-onset-hemorrhagic-cystitis-after 2024-10-21T04:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/0313512974db9775/aao-2024-eyepoint-s-eyp-1901-proves-non-inferiority-to-aflibercept-in-davio-2 2024-10-21T02:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/7b74ba8f94fba86e/aao-2024-rezolute-s-rz-402-shows-promising-phase-iia-results-in-dme-patients 2024-10-21T01:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/5c9afc4c49e17ce8/durga-borkar-md-phase-2-results-of-onl1204-for-rhegmatogenous-retinal-detachment 2024-10-21T01:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/ff9842434ff94e6e/immutep-announces-first-in-human-phase-i-study-of-imp761-progresses-to-dose 2024-10-21T00:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/0e80e4b3357cd358/aprogen-a-company-specializing-in-antibody-drug-development-announced-on-the-21st-that 2024-10-21T00:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/a63f7526b887ae08/recruitment-restarts-in-accent-pancreatic-cancer-trial-biomelbourne-network 2024-10-21T00:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/f3adb2e1762af32e/everest-medicines-announces-taiwan-tfda-approval-of-nefecon-r-for-the-treatment-of 2024-10-21T00:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/98e0670c447b9ae7/accelerated-approval-and-confirmatory-trials-timing-is-everything 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/09a54f4a90699786/glecirasib-pancreatic-cancer-indication-received-orphan 2024-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cdc1af586e9a0143/paradigm-biopharmaceuticals-boosts-confidence-with-phase-3-plans-tipranks-com 2024-10-20T23:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/d33b88a1ea093288/pursuecare-revives-fda-approved-digital-therapeutics-for-addiction-treatment 2024-10-20T23:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/741ba70e7635791f/world-first-clinical-trial-for-treating-spinal-cord-injury-griffith-news 2024-10-20T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/news/a02cd91bd4628772/pyc-therapeutics-gains-fda-approval-for-orphan-drug-tipranks-com 2024-10-20T22:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/594f1f74023dc697/woman-finds-hope-in-new-ms-treatment-wvir 2024-10-20T22:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/83ac8c977efb7268/roger-a-goldberg-md-pooled-visual-function-data-of-nt-501-for-mactel-hcplive 2024-10-20T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/184e9016720b4ff7/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the 2024-10-20T21:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/0058ce4239cf8dad/breakthrough-developments-in-mrna-and-car-t-cell-therapies-reshape-cancer-treatment-landscape 2024-10-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/df952ab63c7bcf3b/treatment-and-survival-of-non-metastatic-small-cell-carcinoma-of-the-bladder-from-multiple 2024-10-20T20:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/477b3a101f942bc6/low-intensity-shockwave-therapy-plasma-injections-efficacious-for-erectile-dysfunction 2024-10-20T20:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/6ea52d58d33c852c/aft-enters-late-stage-r-d-agreement-for-a-novel-injectable-nzx 2024-10-20T19:45:40+00:00 weekly 0.7 https://trial.medpath.com/news/e7f91c7aa7883f07/subcutaneous-efgartigimod-ph20-efficacious-in-patients-with-cidp-previously-treated 2024-10-20T19:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/69766cc3e5e3036e/the-targeted-pulse-explore-how-a-community-practice-implemented-bispecific-antibody 2024-10-20T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/7c675a7a7d6b0d8c/aao-2024-injectable-endothelial-cell-therapy-shows-promise-for-improving-vision-and 2024-10-20T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/eda7a9fe834780bc/can-sharks-cure-cancer-uw-madison-research-shows-positive-advancements-wmtv 2024-10-20T17:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/d352641c564a83d1/flt3-inhibitor-gilteritinib-may-also-be-effective-as-alk-inhibitor-in-aml 2024-10-20T16:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/78034c45622ea306/aao-2024-two-year-clinical-feasibility-trial-outcomes-for-a-dual-optic-iol-system-for-the 2024-10-20T16:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/4f325b0949fe85dd/oral-treatment-aims-to-reduce-ga-progression-by-slowing-vitamin-a-dimerization-healio 2024-10-20T15:35:31+00:00 weekly 0.7 https://trial.medpath.com/news/19a1ef516c6fd174/trs01-drops-display-favorable-clinical-profile-for-non-infectious-uveitis-hcplive 2024-10-20T15:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/5e84204447db96ac/aao-2024-myopic-lasik-performed-using-a-novel-excimer-laser-ophthalmology-times 2024-10-20T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/e5e50ff399030d47/hallmarks-of-a-genomically-distinct-subclass-of-head-and-neck-cancer-nature 2024-10-20T14:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/42d683a6550b8b9e/aao-2024-new-gene-therapy-shows-promise-for-treatment-of-retinitis-pigmentosa 2024-10-20T14:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba5a045130c8f13c/ctdna-clearance-confers-responses-to-radiation-in-gynecologic-malignancies 2024-10-20T14:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/d47be2c7cbd0d47d/aao-2024-clinical-trials-of-travoprost-ophthalmology-times-europe 2024-10-20T14:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/b1a428d749673ab4/weight-loss-jabs-for-unemployed-not-dystopian-says-wes-streeting-bbc 2024-10-20T13:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/900a2b92c0fc6f08/cch-appears-safe-efficacious-in-peyronie-disease-with-ventral-curvature-urology-times 2024-10-20T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/524620cbdcd50b3b/low-blood-s-methyl-5-thioadenosine-is-associated-with-postoperative-delayed-nature 2024-10-20T12:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/a130301ad4886573/foresee-pharmaceuticals-announces-preliminary-results-from-a-phase-1-clinical-trial 2024-10-20T12:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/7a58bf0defd72566/national-fellows-forum-showcases-next-generation-of-lung-cancer-clinicians-onclive 2024-10-20T12:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/8c7177b931b86189/philadelphia-hospitals-test-new-strategy-for-tranq-dope-withdrawal-ems1 2024-10-20T12:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/c968cea430974000/hospital-recruits-five-tiny-babies-for-feeding-study-bbc 2024-10-20T11:52:40+00:00 weekly 0.7 https://trial.medpath.com/news/773e1be599d8edb8/letter-collins-goes-above-and-beyond-for-alzheimer-s-patients-the-portland-press-herald 2024-10-20T11:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/7b27506b0b7f7f9c/how-bad-is-this-news-for-novavax 2024-10-20T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/d526a3360bcf323d/phase-2-study-demonstrates-the-first-successful-clinical-application-of-antifibrotic-therapy-for-breast-cancer 2024-10-20T09:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/f0cfb602119f16cd/study-identifies-approaches-to-address-patient-fears-regarding-jak-inhibitor-safety 2024-10-20T09:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/94bf88c4167c7553/there-is-a-rare-disease-called-idiopathic-pulmonary-fibrosis-ipf-in-which-the-lungs-slowly-harden 2024-10-20T08:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/4909c8a3439e1d1e/expert-takeaway-from-wclc-congress-highlights-innovative-acd-showing-promise-in-sclc 2024-10-20T07:02:06+00:00 weekly 0.7 https://trial.medpath.com/news/1d141db620e2f8d1/semaglutide-boosts-heart-health-weight-loss-but-may-lead-to-gut-problems 2024-10-20T05:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/9e96e5907312917f/invivyd-clinical-efficacy-endpoints-from-the-phase-3-canopy-study-evaluating-pemivibart 2024-10-20T02:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/2c4d9849a625a3bb/distinct-molecular-profiles-and-shared-drug-vulnerabilities-in-pancreatic-metastases-of-renal 2024-10-20T01:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/e12b2ccc4c6c759c/pulsed-shortwave-therapy-did-not-reduce-pain-scores-or-opioid-consumption-after-surgery 2024-10-19T23:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/73cab280015ddf8f/new-fda-approved-vorasidenib-for-idh-mutant-gliomas-survivornet 2024-10-19T23:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/ff2bf9a9f356a519/kerala-joins-icmr-s-clinical-trial-for-indigenous-dengue-vaccine-the-south-first 2024-10-19T23:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/ffd5dbfc69d5e991/1-reason-to-buy-eli-lilly-stock-hand-over-fist-right-now-the-globe-and-mail 2024-10-19T22:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/65b72293eba99d95/tuhura-biosciences-announces-completion-of-merger-transaction-with-kintara-therapeutics 2024-10-19T21:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/8911a94f40009921/comparing-anti-tau-antibodies-under-clinical-trials-and-their-epitopes-on-tau-pathologies 2024-10-19T20:30:59+00:00 weekly 0.7 https://trial.medpath.com/news/de1978e5272b1208/professor-matt-dun-to-be-awarded-australian-society-for-medical-research-medal-hmri 2024-10-19T18:41:59+00:00 weekly 0.7 https://trial.medpath.com/news/ea8c774fa9320524/elevatum-study-s-reason-to-be-underrepresentation-in-clinical-trials-aao-2024 2024-10-19T18:22:57+00:00 weekly 0.7 https://trial.medpath.com/news/faa5dcc9249acb62/evaluating-the-efficacy-of-support-groups-in-the-metaverse-for-ukrainian-refugees-trials 2024-10-19T17:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/9f73a074320e7a14/asciminib-has-superior-response-rates-in-cml-oncology-nursing-news 2024-10-19T17:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/ef28253127220a1c/meta-analysis-reveals-minimal-cognitive-gains-from-antipsychotic-drugs-medical-xpress 2024-10-19T16:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/38f371919a8b4f23/complete-consolidative-radiotherapy-may-have-survival-benefits-in-es-sclc 2024-10-19T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/08a1d5ec051ff81f/a-novel-approach-to-chronic-gvhd-with-axatilimab-dr-daniel-wolff 2024-10-19T15:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/7dcfeccb4521fa26/gvhd-cannot-be-wholly-prevented-so-effective-treatments-are-needed-says-dr-daniel-wolff 2024-10-19T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/62aa9fe629278da1/new-nicotine-inhaler-for-smoking-cessation-moves-to-trial-phase-kfyr 2024-10-19T13:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/708c1b88f1272b81/nurix-therapeutics-presents-positive-results-from-the-ongoing-clinical-trial-of-its-btk 2024-10-19T12:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/200b1c98db2dd951/neoadjuvant-immune-checkpoint-inhibitor-therapy-improves-outcomes-in-early-breast-cancer 2024-10-19T11:59:41+00:00 weekly 0.7 https://trial.medpath.com/news/77b304fd77b8ad8e/zakharia-evaluates-available-combination-options-for-non-clear-cell-rcc 2024-10-19T11:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/d65e006feab71160/stem-cell-treatment-for-regeneration-of-the-rotator-cuff-study-protocol-for-a-prospective-single 2024-10-19T11:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/4cb13564a7b12638/avacta-the-british-biotech-disrupting-cancer-treatment-share-talk 2024-10-19T11:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/c4da053d2f958be5/phase-3-study-reports-similar-efficacy-between-sb17-stelara-in-psoriasis 2024-10-19T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/0c05c4e6af5e9ed0/new-treatments-enhance-care-for-diverse-range-of-patients-with-psoriasis 2024-10-19T10:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/eaa3a1c7682f1531/common-cholesterol-drug-slows-mental-decline-from-alzheimer-s-disease 2024-10-19T10:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/d4586814b3f1f2e1/meta-analysis-reveals-elevated-triglyceride-levels-in-major-depressive-disorder-patients 2024-10-19T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3193a7907f581d05/three-year-results-for-eylea-hd-r-aflibercept-injection-8-globenewswire 2024-10-19T09:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/1187686461e91084/long-term-io-io-data-contest-the-role-of-frontline-tkis-in-advanced-rcc-onclive 2024-10-19T08:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/c6140e9fa503ea15/integrated-cardio-renal-metabolic-care-models-face-implementation-challenges-despite-promise 2024-10-19T07:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3d17c9c9e23ffa4/no-link-found-between-prenatal-cannabis-use-and-early-childhood-disorders 2024-10-19T07:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/43fbc721a3b14b1a/wma-updates-declaration-of-helsinki-with-enhanced-focus-on-research-ethics-and-inclusion 2024-10-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c0f754ec5257a5a4/be-cool-the-briefing-for-18-october-2024-global-competition-review 2024-10-19T04:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/a110c39c1fcf759f/phase-2a-of-cmtx-101-clinical-trial-for-cf-lung-infections-starts 2024-10-19T04:52:06+00:00 weekly 0.7 https://trial.medpath.com/news/f68529d6b2ddf9ef/optimal-timing-for-video-assisted-thoracic-surgery-decortication-for-improved-survival-in 2024-10-19T04:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/55cf6186463c4ade/managing-medication-overuse-headache-in-chronic-migraine-drug-topics 2024-10-19T04:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/82ec65d805e704cd/new-atezolizumab-formulation-for-subcutaneous-injection-research-aacr 2024-10-19T03:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/2351043ed3701ae5/new-cancer-drug-tied-to-vision-loss-study-suggests-becker-s-hospital-review 2024-10-19T03:42:26+00:00 weekly 0.7 https://trial.medpath.com/news/35cb0c05b70e3f1b/tevogen-ceo-expresses-gratitude-for-unprecedented-public-globenewswire 2024-10-19T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/ed6abb3bb3c145fa/tranexamic-acid-for-reduction-of-intra-and-postoperative-transfusion-requirements-in-trials 2024-10-19T02:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/87dfb453a65e7b88/international-medical-graduates-vital-to-addressing-u-s-oncology-workforce-shortage 2024-10-19T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1c1c64bdf5fdd8a7/supernus-depression-drug-improved-symptoms-in-two-hours-in-phase-iia-study 2024-10-19T00:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/a4a54a61c951e5e3/botox-r-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe 2024-10-19T00:13:25+00:00 weekly 0.7 https://trial.medpath.com/news/57a5af70cdd5bbde/real-world-persistence-with-ocrelizumab-in-multiple-sclerosis-patients 2024-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/13befdd53da736c5/bra-lliant-breakthrough-ultrasound-bra-detects-breast-cancer-at-home-wilx 2024-10-18T22:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/0a20f1b34af515b2/boston-scientific-wins-fda-nods-for-nav-enabled-farapulse-catheter-software-massdevice 2024-10-18T22:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/89ee1a5702642051/breakthrough-in-premature-aging-disease-treatment-mirage-news 2024-10-18T22:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/b74d0b7bcb771aba/tiziana-life-sciences-advances-with-promising-drug-trials-tipranks-com 2024-10-18T21:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/19531e77f214d164/ep-104iar-phase-2-data-shows-potential-for-knee-osteoarthritis-pain-hcplive 2024-10-18T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/dfffc5bf538c5748/press-releases-friday-oct-18-2024-genentech 2024-10-18T21:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/1918779c4b2a3d60/neoadjuvant-immunotherapy-for-liver-cancer-shrinking-tumors-growing-responses 2024-10-18T20:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/84ac1ebcb04a4d90/this-week-at-fda-new-guidances-address-cancer-pros-neurodevelopmental-safety 2024-10-18T20:42:44+00:00 weekly 0.7 https://trial.medpath.com/news/fb85cfa468d1563c/selinexor-receives-approval-in-south-korea-for-multiple-myeloma-onclive 2024-10-18T19:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/11a33d6d9a3d3635/cgtlive-r-s-weekly-rewind-october-18-2024 2024-10-18T19:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/b58e2e9f595b7561/successful-special-procedure-study-conduct-cerebrospinal-fluid-csf-and-concurrent 2024-10-18T19:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/d154aa21036b5ea1/partnering-for-precision-in-an-ipf-study-securing-timely-deliverables-and-key-endpoints 2024-10-18T19:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/c194eb13b4b3ddee/fda-pushes-back-decision-on-sotorasib-panitumumab-in-colorectal-cancer 2024-10-18T18:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/a7d44adb4564ecc8/botensilimab-plus-balstilimab-elicits-durable-responses-in-refractory-metastatic-sarcoma 2024-10-18T18:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/ebbc8826c595c9c2/eu-may-approve-oxford-astrazeneca-vaccine-this-week-says-german-health-ministry-spokesman 2024-10-18T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/a87f0306af0de3b1/cognivue-clarity-characterizes-mild-cognitive-impairment-and-alzheimer-s-disease-in-nature 2024-10-18T17:39:31+00:00 weekly 0.7 https://trial.medpath.com/news/89e30792d0c8d7b0/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2024 2024-10-18T17:20:22+00:00 weekly 0.7 https://trial.medpath.com/news/1dde35e8d870e039/tme-pharma-reports-h1-2024-financial-results-and-provides-business-and-clinical-update 2024-10-18T16:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/4f9df05213df46c9/autoantibodies-to-protein-s-may-explain-rare-cases-of-coagulopathy-following-covid-19-vaccination 2024-10-18T16:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/95eb9e2cfac32c05/companies-to-watch-spinogenix-life-science-leader 2024-10-18T16:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/a869d3ab0227392a/european-equities-close-mostly-higher-in-friday-trading-novo-nordisk-s-catalent-tradingview 2024-10-18T16:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/b82d1d911b808d69/a-first-in-class-intracellular-checkpoint-inhibitor-of-dgk-and-z-stemming-from-phenotypic-screening 2024-10-18T15:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/717460a72ac8837a/cancer-s-reign-over-the-drug-development-pipeline-continues-amcp-nexus-2024 2024-10-18T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/849d78bc25c35d4f/a-wechat-platform-program-wcpp-for-full-process-management-of-patients-with-cardiac-trials 2024-10-18T15:41:19+00:00 weekly 0.7 https://trial.medpath.com/news/a90f238f31c7dd21/time-to-sustained-recovery-among-outpatients-with-covid-19-receiving-montelukast-vs-placebo 2024-10-18T15:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/a3347235ece29148/ema-recommends-several-medicines-in-october-biopharm-international 2024-10-18T15:24:19+00:00 weekly 0.7 https://trial.medpath.com/news/93e90239e22d4671/ptc-rebuffed-again-by-ema-novartis-licenses-china-based-biotech-s-cancer-drug 2024-10-18T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/30d47651ed6355d5/fda-issues-bioresearch-monitoring-technical-specifications-document-to-help-you 2024-10-18T15:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/1fc27bc100ec7fa1/the-francis-crick-institute-launches-a-new-project-aimed-at-understanding-immunotherapy-vwv 2024-10-18T14:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/1de79483001d27ca/ucla-study-aims-to-develop-same-day-detection-of-cancer-cells-in-cerebrospinal-fluid 2024-10-18T14:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/369121e9b2633c39/inotuzumab-ozogamicin-in-pediatric-patients-with-relapsed-or-refractory-b-cell-all 2024-10-18T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/79194133034db841/endo-presents-data-at-the-american-society-of-podiatric-surgeons-asps-annual-surgical 2024-10-18T14:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/044f078f20e2a1dc/repurposed-als-drug-shows-promise-against-aggressive-brain-tumors 2024-10-18T14:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/292196629cdd58f2/new-fda-designations-may-jumpstart-gene-therapy-development 2024-10-18T14:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/b752ac45d2ab0cc1/fda-approves-anovo-system-for-abdominal-hernia-repair-the-jerusalem-post 2024-10-18T14:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/702ed31681702df0/ema-awards-prime-status-to-pentixapharm-s-ga68-pentixafor-webdisclosure 2024-10-18T14:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/2d655203fcd11deb/phase-iii-trial-results-of-novel-triple-combination-pill-for-hypertension-published-in-the-lancet 2024-10-18T13:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/84f7b3966e244524/kalvista-pharmaceuticals-to-present-data-at-the-2024-annual-scientific-meeting-of-the-biospace 2024-10-18T13:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/d0565ce4d354d358/can-fite-biopharma-ltd-american-depositary-shares-each-representing-three-hundred 2024-10-18T13:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/f734977d6c3550bb/brown-glaberman-reviews-data-for-pik3ca-altered-metastatic-breast-cancer 2024-10-18T13:38:29+00:00 weekly 0.7 https://trial.medpath.com/news/b68268bed322533e/fda-pushes-back-pdufa-dates-for-amgen-and-intercept-biospace 2024-10-18T13:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/548bfa90cd71af1e/significant-positive-results-from-osteoarthritis-clinical-study-in-dogs-treated-with-piclidenoson 2024-10-18T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/e1ad1f5f50308f3e/aao-2024-livionex-reports-positive-end-of-phase-2-meeting-with-fda-on-the-development 2024-10-18T13:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/d779f2831c05cbb7/cerus-corporation-announces-workshop-and-abstracts-at-the-2024-aabb-annual-meeting 2024-10-18T12:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/a0af981069341559/seastar-medical-announces-that-enrollment-in-its-adult-acute-kidney-injury-pivotal-trial-has 2024-10-18T12:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/d5d9c470168a80fa/gilead-provides-update-on-u-s-indication-for-trodelvy-r-in-metastatic-urothelial-cancer 2024-10-18T12:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/985dde2c54422eff/msd-mulls-2025-26-launch-for-rsv-vaccine-after-phase-ii-iii-win 2024-10-18T12:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/1f343b95d1d8a303/safety-data-help-affirm-adjuvant-alectinib-as-a-new-soc-in-alk-nsclc-onclive 2024-10-18T12:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/1ca71b293edfe6c2/amylyx-s-amx0035-shows-promise-in-phase-ii-wolfram-syndrome-trial 2024-10-18T11:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/eb6bd1a2deb3b683/fda-declares-iv-fluid-shortage-following-hurricane-impact-on-baxter-facilities 2024-10-18T11:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/1b90824ad3e9abab/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1-vegf-biospace 2024-10-18T11:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/08923e4802bd3046/low-dose-bel-sar-shows-promising-safety-efficacy-in-nmibc-in-phase-1-study 2024-10-18T10:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/49f5c881b947f047/real-world-study-confirms-rsv-vaccine-s-protective-power-for-seniors 2024-10-18T10:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/40314d97df6b963a/evergreen-theragnostics-opens-cck2-view-a-phase-ii-small-cell-lung-cancer-clinical-trial 2024-10-18T10:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/407bd2d8193b13b6/translarna-ema-re-confirms-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy 2024-10-18T10:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/25b0553e62f9921a/chmp-recommends-approval-of-novo-nordisk-hemophilia-drug-medwatch 2024-10-18T09:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/a2b1da7ed0d4c30c/response-begins-enrolment-for-trial-of-rdx-002-for-weight-management 2024-10-18T09:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/98319b342976219f/novo-nordisk-a-s-alhemo-r-recommended-for-european-approval-globenewswire 2024-10-18T09:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/6339eed2a494d097/risk-stratification-and-population-health-key-to-revolutionizing-ckd-care-management 2024-10-18T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/f0506b657a9eeccd/early-phase-clinical-trials-for-the-development-of-novel-immunotherapeutic-anti-cancer-agents 2024-10-18T08:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/d2cc77846e6a89e7/social-determinants-create-stark-disparities-in-type-2-diabetes-care-and-outcomes 2024-10-18T08:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/a3145bb2ca9e45f8/cell-therapy-weekly-us-225-million-investment-towards-world-class-research-institute 2024-10-18T07:51:38+00:00 weekly 0.7 https://trial.medpath.com/news/ee9052dc7f5343c0/landmark-unmc-research-studies-abc-s-of-icu-care-newsroom 2024-10-18T07:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/4101db9370bd957b/nitrogen-dioxide-air-pollution-linked-to-21-higher-ovarian-cancer-risk-in-us-study 2024-10-18T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a49cb044d53d598e/vaccine-against-the-mers-coronavirus-tested-as-safe-and-effective-in-phase-ib-clinical-trial 2024-10-18T06:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/be1f4a0ae5449197/ondine-biomedical-steriwave-receives-uae-regulatory-approval-research-tree 2024-10-18T06:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/c4ffbe9e7cdd328c/cancer-clinical-trials-receive-22m-funding-boost-hospital-healthcare 2024-10-18T05:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/152d8629c60f9428/machine-learning-based-model-for-cd4-conventional-t-cell-genes-to-predict-survival-and 2024-10-18T05:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/397b804f0a1e6279/phase-2-trial-of-psma-pet-ct-versus-planar-bone-scan-and-ct-in-prostate-cancer-patients-nature 2024-10-18T03:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/f0dd8243fa46374c/comparing-remimazolam-and-propofol-for-postoperative-anesthesia-satisf-dddt 2024-10-18T03:54:37+00:00 weekly 0.7 https://trial.medpath.com/news/c10d6ec9678dcf30/inhalerx-procures-38-5m-in-funding-from-clendon-biotech-to-progress-inhaled-therapies 2024-10-18T03:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/4f3a342ad90d590c/study-finds-ezetimib-rifampin-may-increase-coproporphyrin-concentrations-in-healthy-patients 2024-10-18T01:24:48+00:00 weekly 0.7 https://trial.medpath.com/news/4ec78030ba4aa90e/gilead-announces-plans-to-voluntarily-withdraw-the-u-s-accelerated-approval-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-18T01:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/4ae17392d3ca9363/promising-growth-and-innovation-drive-buy-recommendation-for-rapport-therapeutics-inc 2024-10-18T00:36:20+00:00 weekly 0.7 https://trial.medpath.com/news/d1b38402e20fa042/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-18T00:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/e439a71eb5a0e4f2/unlearn-s-digital-twins-slash-pharma-trial-costs-by-millions-drug-discovery-and-development 2024-10-17T23:31:04+00:00 weekly 0.7 https://trial.medpath.com/news/c24441c71aaecbdb/nih-awards-acri-2-9-million-for-critical-cystic-fibrosis-therapy-research 2024-10-17T22:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/f1a4abbab28282a8/merck-s-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv 2024-10-17T22:25:21+00:00 weekly 0.7 https://trial.medpath.com/news/2dd663402b0328e1/tryptamine-therapeutics-advances-psilocin-drug-trials-tipranks-com 2024-10-17T22:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/aa0c246a0f03ceff/lexicon-sells-viatris-rights-to-cardio-drug-outside-of-the-u-s-and-europe-biopharma-dive 2024-10-17T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/e9e3b938c85f38ba/dr-nowakowski-on-the-implications-of-the-fda-approval-of-epcoritamab-in-follicular-lymphoma 2024-10-17T20:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/685a94a7043cfdc2/cabozantinib-plus-atezolizumab-fails-to-improve-os-over-subsequent-novel-hormonal 2024-10-17T20:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/82aa1eb27cc19dc5/fda-approval-insights-denileukin-diftitox-in-relapsed-refractory-ctcl-onclive 2024-10-17T20:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/197b31ac05dda922/sage-lays-off-55-of-r-d-workforce-and-refocuses-pipeline-yahoo-finance 2024-10-17T19:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/941d32859ce5c313/intercept-s-liver-disease-drug-faces-full-approval-delay-following-negative-adcomm 2024-10-17T19:45:48+00:00 weekly 0.7 https://trial.medpath.com/news/21ced478e33f5e47/the-positive-choices-trial-update-to-study-protocol-for-a-phase-iii-rct-trial-of-a-whole-trials 2024-10-17T19:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/a2238111bc6f760d/3-takeaways-from-bcrf-s-webinar-on-metastatic-breast-cancer 2024-10-17T19:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/0c036aee39ae38e3/mcgregor-and-participants-discuss-impact-of-drug-efficacy-and-histology-on-nccrcc-care 2024-10-17T19:02:12+00:00 weekly 0.7